# Patent

## Title
Markers associated with Alzheimer'S disease

## Abstract

This application discloses SNPs capable of predicting increased or decreased risk of developing late onset Alzheimer's disease.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 USC 119(e) of U.S. Provisional Patent Application No. 61/312,855, filed Mar. 11, 2010, which is incorporated herein by reference in its entirety for all purposes.
SEQUENCE LISTING
This application contains a sequence listing in computer readable format, the teachings and content of which are hereby incorporated by reference.


FIELD
The present invention relates to genetic markers, compositions for the detection of genetic markers, and methods for assessing risk of developing Alzheimer's disease.
BACKGROUND
Disorders of the brain are serious medical conditions causing disability and diminished quality of life. Neurological damage is largely irreversible and thus early diagnosis and close monitoring are critical to the successful treatment of patients. Alzheimer's disease (AD) is a neurodegenerative disease associated with progressive memory loss and cognitive dysfunction. It is associated with abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles) in the brain, both of which are considered signs of AD. An estimated 4 million Americans have AD. By the year 2030 approximately 1 in every 80 persons in the U.S. will have AD. Familial Alzheimer's disease (FAD) is known to be inherited. In affected families, members of at least two generations have had the disease. FAD is rare, accounting for less than 1% of all cases of AD. FAD has an earlier onset, i.e., about 40 years of age and can be observed to run in families.
Early-onset Alzheimer's disease (EOAD) is a rare form of Alzheimer's disease in which individuals are diagnosed with the disease before age 65. Less than 10% of all Alzheimer's disease patients have EOAD. Younger individuals who develop Alzheimer's disease exhibit more of the brain abnormalities that are normally associated with Alzheimer's disease. EOAD is usually familial and follows an autosomal dominant inheritance pattern. To date, mutations in three genes including amyloid precursor protein (APP) on chromosome 21, presenilin 1 (PSEN1) on chromosome 14 and presenilin 2 (PSEN2) on chromosome 1 have been identified in families with EOAD. Mutations in the APP, PSEN1 and PSEN2 genes account for about 50% of the disease. Most of the pathogenic mutations in the APP and presenilin genes are associated with abnormal processing of APP, which leads to the overproduction of toxic A ̃−1-42. Down syndrome patients, who have three copies of chromosome 21 which includes the APP gene, begin to develop the characteristic senile plaques and tau tangles at the ages of 30 and 40 (Kamboh, Annals of Human Genetics 68:381-404, 2004).
Late-onset Alzheimer's disease (LOAD) is the most common form of Alzheimer's disease, accounting for about 90% of cases and usually occurring after age 65. LOAD strikes almost half of all individuals over the age of 85 and may or may not be hereditary. It is a complex and multifactorial disease with the possible involvement of several genes. Genome-wide linkage or linkage disequilibrium studies on LOAD have provided informative data for the existence of multiple putative genes for AD on several chromosomes, with the strongest evidence on chromosomes 12, 10, 9 and 6. LOAD cases tend to be sporadic, wherein there is no family history of the disease. Genetic susceptibility at multiple genes and interaction between these genes as well as environmental factors are most likely responsible for the etiology of LOAD. Twin data on incident cases indicates that almost 80% of the LOAD risk is attributable to genetic factors. The Apolipoprotein E (APOE) gene on chromosome 19q13 has been identified as a strong risk factor for LOAD. In fact, the APOE-ε4 allele has been established as a strong susceptibility marker that accounts for nearly 30% of the risk in late-onset AD. More specifically, three variants of APOE, encoded by codons 112 and 158, have been found to modify the risk of LOAD. As compared to the common APOE-ε3 allele (codon 112=Cys and codon 158=Arg), the APOE-ε4 allele (codon 112=Arg and codon 158=Arg) increases the risk of AD, while the APOE-ε2 allele (codon 112=Cys and codon 158=Cys) decreases the risk of AD. The effect of the APOE-ε4 allele is dose related, wherein one or two copies of the APOE-ε4 allele are associated with 3-fold or 15-fold risk, respectively. However, the effect of the APOE-ε4 allele on AD risk appears to decline with increasing age (Kamboh, 2004, supra).
From the time of diagnosis, people with AD survive about half as long as those of similar age without dementia. Medicare costs for beneficiaries with AD were $91 billion in 2005 and may increase to as much as $160 billion in 2010. Finding a treatment that could delay the onset by five years could reduce the number of individuals with AD by nearly 50 percent after 50 years. Drug development for AD is very active and sensitive diagnostic and screening technologies could identify patients for therapy and monitor their response. Improved diagnostic tools for AD would thus be a significant advancement to drug development for this disease and would also provide a way to guide therapeutic decision making thus improving outcomes and reducing unnecessary exposure of patients to costly medications with unwanted side effects.
SUMMARY
The present invention relates to genetic markers, compositions for the detection of genetic markers, and methods for assessing risk of developing Alzheimer's disease.
In particular, the present invention provides methods of classifying a subject to a late onset Alzheimer's disease risk group, comprising: receiving a sample from the subject; detecting a marker in Table 2; and classifying the subject into a risk group based upon the presence or absence of the marker. In some embodiments, the methods further comprising isolating nucleic acid from the sample. In some embodiments, the marker is detected directly. In some of these embodiments, the marker detection comprises a method selected from the group consisting of Sanger sequencing, pyrosequencing, SOLID sequencing, massively parallel sequencing, barcoded DNA sequencing, PCR, real-time PCR, quantitative PCR, microarray analysis of genomic DNA with a gene chip, restriction fragment length polymorphism analysis, allele specific ligation, and comparative genomic hybridization. In other embodiments, the marker is detected indirectly. In some of these embodiments, the marker detection comprises a method selected from the group consisting of microarray analysis of RNA, RNA in situ hybridization, RNAse protection assay, Northern blot, reverse transcriptase PCR, quantitative PCR, quantitative reverse transcriptase PCR, quantitative real-time reverse transcriptase PCR, reverse transcriptase treatment followed by direct sequencing, flow cytometry, immunohistochemistry, ELISA, Western blot, immunoaffinity chromatograpy, HPLC, mass spectrometry, protein microarray analysis, PAGE analysis, isoelectric focusing, and 2-D gel electrophoresis. In some embodiments, the marker is associated with a high risk of developing LOAD and the subject is classified to a risk group with high risk of LOAD if the marker is detected in the sample. In a subset of these embodiments, the subject is further classified based on the presence or absence of the APOE-ε4 allele. In some embodiments, the marker is associated with a low risk of developing LOAD and the subject is classified to a risk group with low risk of LOAD if the marker is detected in the sample. In a subset of these embodiments, the marker is the A allele of rs17042395. In some embodiments, the subject is further classified based on the presence of two copies of the APOE-e3 allele.
In addition, the present invention provides sets of molecular probes used in assessing the risk of developing late onset Alzheimer's disease (LOAD) comprising: a first probe capable of detecting a first SNP selected from Table 2; and a second probe capable of detecting a second SNP selected from Table 2; wherein the probes are associated with a microarray of 1000 or fewer elements. In some embodiments, the first probe is capable of detecting a SNP associated with a higher risk of developing LOAD. In some embodiments, the second probe is capable of detecting a SNP associated with a lower risk of developing AD. In other embodiments, the first probe and the second probe are capable of detecting a SNP associated with a lower risk of developing LOAD. In some preferred embodiments, the first probe detects the A allele of rs17042395 and the second probe detects the apoe3 allele.
Moreover, the present invention provides methods of classifying a subject to a late onset Alzheimer's disease (LOAD) risk group, comprising: receiving a sample from the subject; detecting an A allele of rs17042395; detecting an E3 allele of APOE; and classifying the subject in a low LOAD risk group if both the A allele of rs17042395 and the E3 allele of APOE are detected. In some embodiments, the methods further comprise isolating nucleic acid from the sample. In some embodiments, the marker is detected directly. In some of these embodiments, the marker detection comprises a method selected from the group consisting of Sanger sequencing, pyrosequencing, SOLID sequencing, massively parallel sequencing, barcoded DNA sequencing, PCR, real-time PCR, quantitative PCR, microarray analysis of genomic DNA with a gene chip, restriction fragment length polymorphism analysis, allele specific ligation, and comparative genomic hybridization. In some embodiments, the marker is detected indirectly. In some of these embodiments, the marker detection comprises a method selected from the group consisting of microarray analysis of RNA, RNA in situ hybridization, RNAse protection assay, Northern blot, reverse transcriptase PCR, quantitative PCR, quantitative reverse transcriptase PCR, quantitative real-time reverse transcriptase PCR, reverse transcriptase treatment followed by direct sequencing, flow cytometry, immunohistochemistry, ELISA, Western blot, immunoaffinity chromatograpy, HPLC, mass spectrometry, protein microarray analysis, PAGE analysis, isoelectric focusing, and 2-D gel electrophoresis.


DETAILED DESCRIPTION
In the following description, and for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the invention. It will be understood, however, by those skilled in the relevant arts, that the present invention may be practiced without these specific details. In other instances, known structures and devices are shown or discussed more generally in order to avoid obscuring the invention.
Aspects and applications of the invention presented here are described below in the drawings and detailed description of the invention. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts.
If a noun, term, or phrase is intended to be further characterized, specified, or narrowed in some way, then such noun, term, or phrase will expressly include additional adjectives, descriptive terms, or other modifiers in accordance with the normal precepts of English grammar. Absent the use of such adjectives, descriptive terms, or modifiers, it is the intent that the noun, term, or phrase is given its broadest possible meaning.
The use of the words “function,” “means” or “step” herein is not intended to somehow indicate a desire to invoke the special provisions of 35 U.S.C. §112, ¶6, to define the invention. To the contrary, if the provisions of 35 U.S.C. §112, ¶6 are sought to be invoked to define the inventions, the claims will specifically and expressly state the exact phrases “means for” or “step for, and will also recite the word “function” (i.e., will state “means for performing the function of [insert function]”), without also reciting in such phrases any structure, material or act in support of the function. Thus, even when the claims recite a “means for performing the function of . . . ” or “step for performing the function of . . . ,” if the claims also recite any structure, material or acts in support of that means or step, or that perform the recited function, then the provisions of 35 U.S.C. §112, ¶6 are not invoked. Moreover, even if the provisions of 35 U.S.C. §112, ¶6 are invoked to define the claimed inventions, it is intended that the inventions not be limited only to the specific structure, material or acts that are described in the preferred embodiments, but in addition, include any and all structures, materials or acts that perform the claimed function as described in alternative embodiments or forms of the invention, or that are well known present or later-developed, equivalent structures, material or acts for performing the claimed function.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory and cognitive impairments and other non-cognitive behavioral symptoms. Age is the strongest risk factor, wherein almost 50% of people over the age of 85 are affected. Early onset AD (EOAD) is associated with genetic mutations in amyloid precursor protein (APP), presenilin I (PSENI) and presenilin 2 (PSEN2). However, sporadic or late-onset AD (LOAD) is multi-factorial and genetically more complex. In addition, genetic factors may account for as much as 80% of the disease risk associated with LOAD (Gatz et al. (2006) Arch. Gen. Psychiatry 63(2):168-174). While monogenic mutations cause EOAD, the only extensively validated susceptibility gene for LOAD is the apolipoprotein E (APOE-e4) allele (Saunders et al. (1993) Neurology 43(8):1467-1472 and Farrer et al. (1997) JAMA 278(16): 1349-1356). But alleles of the APOE gene do not account for all of the genetic load responsible for LOAD predisposition. Stratification by APOE-ε4 carrier status allows for the detection of association signals that are normally overwhelmed and thus, masked by the signal of APOE alleles in a non-stratified study design.
AD is the most common cause of disabling memory and thinking problems in older persons. According to one study, it afflicts about 10% of those over the age of 65 and almost half of those over the age of 85. According to another study, the prevalence of the disorder increases from I % by the age of 60 years to 40% in nonagenarians (See Reference 1). By 2050, the number of afflicted persons is projected to quadruple, leading to  ̃16 million patients and a cost of more than $750 billion per year (with no adjustment for inflation) in the United States alone. Meantime, the disorder takes a devastating toll on patients and their families. Clinically, AD is characterized by gradual but progressive declines in memory, language skills, ability to recognize objects or familiar faces, ability to perform routine tasks, and judgment and reasoning. Associated features commonly include agitation, paranoid delusions, sleepiness, aggressive behaviors, and wandering. In its most severe form, patients may be confused, bed-ridden, unable to control their bladder or bowel functions, or swallow. By contributing to other problems (e.g., inanition and infections), it is considered the fourth leading cause of death in the United States. Neuropathologically, AD is characterized by the accumulation of neuritic plaques (the major component of which is the amyloid-B peptide [Aβ], neurofibrillary tangles (NFT, the major component of which is the hyper-phosphorylated form of the protein tau). While the etiology leading to the development of AD has not been clearly resolved, genetic factors play a major role.
Twin studies report a higher concordance of AD among monozygotic compared to dizygotic twins, with heritability estimates between 60% and 80% (See Reference 2). Some rare forms of the disease (<1% by some estimates) are caused by more than 200 mutations in the genes encoding the amyloid precursor protein (APP), presenilin I (PSI) and presenilin 2 (PS2). These mutations, which influence directly the production of Aβ, cause a form of AD characterized by autosomal dominant inheritance and an early age of dementia onset (typically before the age of 60). However, the majority of AD cases are not dominantly inherited and there is a broad consensus that AD is genetically complex and heterogeneous and that genetic polymorphisms contribute substantially to the risk of disease.
The ε4 allele of the apolipoprotein E (APOE) genotype is the only well-established genetic susceptibility factor for sporadic or familial AD (See Reference 4). While subsequent association studies have suggested the existence of additional AD susceptibility genes, most of the results have not been replicated consistently. A variety of approaches, each with its strengths and limitations, are being taken in an attempt to discover additional AD susceptibility genes. One approach is the use of genome-wide scans.
Large case-control association studies are one approach being to identify genes that predispose to genetically complex neuropsychiatric disorders (See Reference 8). In AD, the candidate-gene approach has been mostly used in case-control association studies because it is straightforward and because it uses information generated in previous epidemiologic studies or laboratory experiments. The development of dense, genome-wide genotyping technologies such as the 100 k and 500 k SNP genotyping chips by Affymetrix allowed, for the first time, a hypothesis-free approach in the genetics of such complex diseases as AD. Reiman et al. previously applied this approach to a set of 1,411 samples that included 1,044 post-mortem neuropathologically verified cases and controls. After multiple testing corrections, the only locus that remained significant in the whole genome screen was APOE (See Reference 9).
Based on the hypothesis that the signal from APOE could be overwhelming other significantly associated loci, the cohort was stratified into those who were carriers of the APOE-ε4 risk allele and those who were non-carriers and the analysis was repeated in these subgroups. Among those who were carriers of APOE-ε4, a significant association was detected between AD and the Grb-2 associated binding protein (GAB2) (See Reference 10). Set association analysis also produced a set of 5 SNPs that improved genetic risk assessment of late onset AD, particularly for those who were not carriers of the APOE-ε4 risk allele.
In people with AD, changes in the brain may begin 10 to 20 years before any visible signs or symptoms appear. Some regions of the brain may begin to shrink, resulting in memory loss, the first visible sign of AD. Over time, AD progresses through three main stages: mild, moderate, and severe. These stages are characterized by a collection of signs and symptoms and behaviors that individuals with AD experience. People with mild symptoms of AD often seem healthy, but they are actually having difficulty making sense of the world around them. Initial symptoms are often confused with changes that take place in normal aging. Symptoms and early signs of AD may include difficulty learning and remembering new information, difficulty managing finances, planning meals, taking medication on schedule, depression symptoms (sadness, decreased interest in usual activities, loss of energy), getting lost in familiar places, etc. In moderate AD, the damaging processes occurring in the brain worsen and spread to other areas that control language, reasoning, sensory processing, and thought. In this stage, symptoms and signs of AD become more pronounced and behavioral problems may become more obvious. Signs and symptoms of moderate AD may include forgetting old facts, repeating stories and/or questions over and over, making up stories to fill gaps, difficulty performing tasks, following written notes, agitation, restlessness, repetitive movements, wandering, paranoia, delusions, hallucinations, deficits in intellect and reasoning, lack of concern for appearance, hygiene, and sleep, etc. In the advanced stage of AD, damage to the brain's nerve cells is widespread. At this point, full-time care is typically required. People with severe AD may have difficulty walking, and they often suffer complications from other illnesses, such as pneumonia. Signs of severe AD may include screaming, mumbling, speaking gibberish, refusing to eat, failing to recognize family or faces, and difficulty with all essential activities of daily living.
A single polynucleotide polymorphism (or SNP) may be any DNA sequence variation that involves a change in a single nucleotide.
A haplotype may be any combination of one or more closely linked alleles inherited as a unit. Different combinations of polymorphisms may also be called haplotypes. The difference of a single genetic marker can delineate a distinct haplotype. Alternatively, the results from several loci could be referred to as a haplotype. For example, a haplotype can be a set of SNPs on a single chromatid that are statistically associated to be likely to be inherited as a unit. Two or more alleles likely to be inherited as a unit may be termed a haplotype block. The haplotype block may, in turn, be used to identify other polymorphic sites in its region. Upon identification of a haplotype block associated with a particular haplotype, one of skill in the art may readily identify all other DNA polymorphisms associated with the particular haplotype by routine sequencing of the genomic DNA of an individual having such haplotype (such as an individual homozygous for such haplotype).
An allele includes any form of a particular nucleic acid that may be recognized as a form of the particular nucleic acid on account of its location, sequence, or any other characteristic. Alleles include but need not be limited to forms of a gene that include point mutations, silent mutations, deletions, frameshift mutations, single nucleotide polymorphisms (SNPs), inversions, translocations, heterochromatic insertions, and differentially methylated sequences relative to a reference gene, whether alone or in combination. The presence or absence of an allele may be detected through the use of any process through which a specific nucleic acid molecule may be detected, including direct and indirect methods of detecting the presence or absence of an allele. An allele may occur in a non-coding or coding region of a genome. If it is in a coding region, it may affect a particular triplet codon. If the allele does affect the codon, it may change the amino acid in the protein resulting from expression of the allele. An exception is if the allele is a silent mutation. In that case, the allele is a mutation in the coding region that does not change the amino acid that the codon encodes. An allele may also be called a mutation or a mutant. An allele may be compared to another allele that may be termed a wild type form of an allele. In some cases, the wild type allele is more common than the mutant.
When a SNP haplotype block is identified by a SEQ ID NO, a set of at least two SNPs that are associated with an allele of a gene are grouped together in the form of a synthetic nucleotide sequence. Detecting the SNPs in a given haplotype block in a subject may be associated with a greater or lesser risk that the subject will develop LOAD. A nucleic acid may be termed to be specific to a SNP haplotype block or specific to a SNP within a haplotype block. A nucleic acid specific to a haplotype block or a SNP within a haplotype block contains sequence that is complementary to at least one SNP that is grouped within that haplotype block. Such nucleic acids may be complementary to a SNP that is associated with the synthetic nucleotide sequence or any other SNP associated within the haplotype identified by the SNP haplotype block.
The HapMap is a catalog of common genetic variants that occur in human beings. It describes what these variants are, where they occur in the DNA, and how they are distributed among individuals within populations and among populations in different parts of the world (See the following reference: A haplotype map of the human genome (2005) Nature 437:1299-1320).
A marker may be any molecular structure produced by a cell, expressed inside the cell, accessible on the cell surface, or secreted by the cell. A marker may be any protein, carbohydrate, fat, nucleic acid, catalytic site, or any combination of these such as an enzyme, glycoprotein, cell membrane, virus, cell, organ, organelle, or any uni- or multimolecular structure or any other such structure now known or yet to be disclosed whether alone or in combination. A marker may also be called a target and the terms are used interchangeably.
A marker may be represented by the sequence of a nucleic acid from which it can be derived or any other chemical structure. Examples of such nucleic acids include miRNA, tRNA, siRNA, mRNA, cDNA, or genomic DNA sequences including complimentary sequences. Alternatively, a marker may be represented by a protein sequence. The concept of a marker is not limited to the products of the exact nucleic acid sequence or protein sequence by which it may be represented. Rather, a marker encompasses all molecules that may be detected by a method of assessing the expression of the marker.
Examples of molecules encompassed by a marker represented by a particular sequence or structure include point mutations, silent mutations, deletions, frameshift mutations, translocations, alternative splicing derivatives, differentially methylated sequences, differentially modified protein sequences, truncations, soluble forms of cell membrane associated markers, and any other variation that results in a product that may be identified as the marker. The following nonlimiting examples are included for the purposes of clarifying this concept: If expression of a specific marker in a sample is assessed by RTPCR, and if the sample expresses an mRNA sequence different from the sequence used to identify the specific marker by one or more nucleotides, but the marker may still be detected using RTPCR, then the specific marker encompasses the sequence present in the sample. Alternatively if expression of a specific marker in a sample is assessed by an antibody and the amino acid sequence of the marker in the sample differs from a sequence used to identify marker by one or more amino acids, but the antibody is still able to bind to the version of the marker in the sample, then the specific marker encompasses the sequence present in the sample.
The genetic sequences of different individuals are remarkably similar. When the chromosomes of two humans are compared, their DNA sequences can be identical for hundreds of bases. But at about one in every 1000 to 1,200 bases, on average, the sequences will differ. As such, one individual might have an A at that location, while another individual has a G, or a person might have extra bases at a given location or a missing segment of DNA. Differences in individual bases are the most common type of genetic variation. These genetic differences are known as single nucleotide polymorphisms (SNPs) (supra). SNPs act as markers to locate genes in DNA. Given the relatively close spacing between these SNPs, SNPs are typically inherited in blocks.
The invention provides a method of assigning a subject to a late onset Alzheimer's disease (LOAD) risk group in order to assess the likelihood of the subject being afflicted with the disease. This method can be employed to assess the risk at early stages of disease progression. The method includes providing a biological sample from the subject, detecting a marker in a biological sample, which can be a haplotype associated with LOAD and assigning the subject to the late onset Alzheimer's disease (LOAD) risk group based upon the presence or absence of the haplotype. The method involves directly or indirectly detecting the presence or absence of the markers. In addition, the subject may be further stratified by LOAD risk group based upon whether the subject carries an apolipoprotein E allele associated with increased or altered LOAD risk. By way of example, APOE-ε4 is commonly associated with LOAD. In addition, various haplotypes of APOE have been associated with LOAD risk groups as set forth in U.S. Patent Publ. 2005/0277129. Finally multiple markers disclosed herein may be used in combination to improve the accuracy, preferably two or more, three or more, four or more, five or more, or ten or more of the markers may be used.
The invention contemplates that markers may be detected by a variety of methodologies or procedures that are well know in the art including, but not limited to, nucleic acid hybridization, antibody binding, activity assay, polymerase chain reaction (PCR), SI nuclease assay and via gene chip or microarray as well as any other assay known in the art that may be used to detect the SNPs associated with a haplotype or the gene product produced from the gene of the haplotype including mRNA and protein. Hybridization of a SNP-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin interactions, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. SNP-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis. Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads. The solid support may be treated, coated or derivatized to facilitate the immobilization of the SNP-specific oligonucleotide or target nucleic acid. Detecting the nucleotide or nucleotide pair of interest may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al. (1985) Proc. Natl. Acad. Sci. USA 82:7575; Meyers et al. (1985) Science 230:1242) and proteins which recognize nucleotide mismatches, such as the E. coli mutS protein (Modrich (1991) Ann. Rev. Genet. 25:229-53). Alternatively, variant SNPs or variant alleles can be identified by single strand conformation polymorphism (SSCP) analysis (Orita et at. (1989) Genomics 5:874-9); Humphries et al. (1996) in MOLECULAR DIAGNOSIS OF GENETIC DISEASES, Elles, ed., pp. 321-340) or denaturing gradient gel electrophoresis (DGGE) (Wartell et al. (1990) Nucl. Acids Res. 18:2699706); Sheffield et al. (1989) Proc. Natl. Acad. Sci. USA 86:232-6). A polymerase-mediated primer extension method may also be used to identify the polymorphism(s). Several such methods have been described in the patent and scientific literature and include the “Genetic Bit Analysis” method (WO 92/15712) and the ligase/polymerase mediated genetic bit analysis (U.S. Pat. No. 5,679,524. Related methods are disclosed in WO 91102087, WO 90/09455, WO 95/17676, and U.S. Pat. Nos. 5,302,509 and 5,945,283. Extended primers containing the complement of the polymorphism may be detected by mass spectrometry as described in U.S. Pat. No. 5,605,798. Another primer extension method is allele-specific PCR (Ruano et al. (1989) Nucl. Acids Res. 17:8392; Ruano et al. (1991) Nucl. Acids Res. 19:6877-82); WO 93/22456; Turki et al. (1995) 1. Clin. Invest. 95:1635-41). The haplotype for a gene of an individual may also be determined by hybridization of a nucleic acid sample containing one or both copies of the gene, mRNA, cDNA or fragment(s) thereof, to nucleic acid arrays and sub-arrays such as described in WO 95/112995. The arrays would contain a battery of SNP-specific or allele specific oligonucleotides representing each of the polymorphic sites to be included in the haplotype.
Detecting the presence or absence of a marker disclosed herein or a close isoform thereof may be carried out either directly or indirectly by any suitable methodology. A variety of techniques are known to those skilled in the art (supra). All generally involve receiving a biological sample containing DNA or protein from the subject, and then detecting whether or not the marker or a close isoform thereof is present in the sample. and then determining the presence or absence of the marker in the sample.
The sample may be any type of sample derived from the subject, including any fluid or tissue that may contain one or more markers associated with the haplotype. Examples of sources of samples include but are not limited to biopsy or other in vivo or ex vivo analysis of prostate, breast, skin, muscle, fascia, brain, endometrium, lung, head and neck, pancreas, small intestine, blood, liver, testes, ovaries, colon, skin, stomach, esophagus, spleen, lymph node, bone marrow, kidney, placenta, or fetus. In some aspects of the invention, the sample comprises a fluid sample, such as peripheral blood, lymph fluid, ascites, serous fluid, pleural effusion, sputum, cerebrospinal fluid, amniotic fluid, lacrimal fluid, stool, or urine.
The marker may be detected by any of a number of methods. Direct methods of detecting the presence of an allele include but are not limited to any form of DNA sequencing including Sanger, next generation sequencing, pyrosequencing, SOLID sequencing, massively parallel sequencing, pooled, and barcoded DNA sequencing or any other sequencing method now known or yet to be disclosed; PCR-based methods such as real-time PCR, quantitative PCR, reverse transcription PCR or any combination of these; allele specific ligation; comparative genomic hybridization; or any other method that allows the detection of a particular nucleic acid sequence within a sample or enables the differentiation of one nucleic acid from another nucleic acid that differs from the first nucleic acid by one or more nucleotides. A sample may be from a subject suspected of having AD. Nucleic acids may include but need not be limited to RNA, cDNA, tRNA, mitochondrial DNA, plasmid DNA, siRNA, genomic DNA, or any other naturally occurring or artificial nucleic acid molecule. A subject may be any organism that may be subject to degenerative neurological diseases including mammals, further including humans.
In Sanger Sequencing, a single-stranded DNA template, a primer, a DNA polymerase, \nucleotides and a label such as a radioactive label conjugated with the nucleotide base or a fluorescent label conjugated to the primer, and one chain terminator base comprising a dideoxynucleotide (ddATP, ddGTP, ddCTP, or ddTTP, are added to each of four reaction (one reaction for each of the chain terminator bases). The sequence may be determined by electrophoresis of the resulting strands. In dye terminator sequencing, each of the chain termination bases is labeled with a fluorescent label of a different wavelength which allows the sequencing to be performed in a single reaction.
In pyrosequencing, the addition of a base to a single stranded template to be sequenced by a polymerase results in the release of a phyrophosphate upon nucleotide incorporation. An ATP sulfyrlase enayme converts pyrophosphate into ATP which in turn catalyzes the conversion of luciferin to oxyluciferin which results in the generation of visible light that is then detected by a camera.
In SOLID sequencing, the molecule to be sequenced is fragmented and used to prepare a population of clonal magnetic beads (in which each bead is conjugated to a plurality of copies of a single fragment) with an adaptor sequence and alternatively a barcode sequence. The beads are bound to a glass surface. Sequencing is then performed through 2-base encoding.
In massively parallel sequencing, randomly fragmented targeted DNA is attached to a surface. The fragments are extended and bridge amplified to create a flow cell with clusters, each with a plurality of copies of a single fragment sequence. The templates are sequenced by synthesizing the fragments in parallel. Bases are indicated by the release of a fluorescent dye correlating to the addition of the particular base to the fragment.
Examples of indirect methods of detection include any nucleic acid detection method including the following nonlimiting examples, microarray analysis, RNA in situ hybridization, RNAse protection assay, Northern blot, reverse transcriptase PCR, quantitative PCR, quantitative reverse transcriptase PCR, quantitative real-time reverse transcriptase PCR, reverse transcriptase treatment followed by direct sequencing, direct sequencing of genomic DNA, or any other method of detecting a specific nucleic acid now known or yet to be disclosed. Other examples include any process of assessing protein expression including flow cytometry, immunohistochemistry, ELISA, Western blot, and immunoaffinity chromatograpy, HPLC, mass spectrometry, protein microarray analysis, PAGE analysis, isoelectric focusing, 2-D gel electrophoresis, or any enzymatic assay.
Other methods used to assess expression include the use of natural or artificial ligands capable of specifically binding a marker. Such ligands include antibodies, antibody complexes, conjugates, natural ligands, small molecules, nanoparticles, or any other molecular entity capable of specific binding to a marker. Antibodies may be monoclonal, polyclonal, or any antibody fragment including an Fab, F(ab)2, Fv, scFv, phage display antibody, peptibody, multispecific ligand, or any other reagent with specific binding to a marker. Ligands may be associated with a label such as a radioactive isotope or chelate thereof, dye (fluorescent or nonfluorescent) stain, enzyme, metal, or any other substance capable of aiding a machine or a human eye from differentiating a cell expressing a marker from a cell not expressing a marker. Additionally, expression may be assessed by monomeric or multimeric ligands associated with substances capable of killing the cell. Such substances include protein or small molecule toxins, cytokines, pro-apoptotic substances, pore forming substances, radioactive isotopes, or any other substance capable of killing a cell.
Other markers may also be used that are associated with the markers disclosed herein such as SNPs or other polymorphic markers that are in close enough proximity to have a statistically significant association with the marker disclosed herein (i.e., other markers in linkage disequilibrium with a marker disclosed herein). For example, if a marker or a close isoform thereof is detected in the subject, then the subject may be placed into a group either at higher or lower risk for LOAD depending on which marker or close isoform thereof is identified (i.e., a significant enough number of markers associated with a haplotype).
The invention also provides set of molecular probes for detection, including at least two probes capable of detecting, directly or indirectly, a marker disclosed herein associated with increased or decreased risk of LOAD, wherein the molecular probes are not associated with a microarray of greater than 1000 elements, a microarray with greater than 500 elements, a microarray with greater than 100 elements, a microarray with greater than 50 elements, or are not associated with a microarray. Such sets of two or more probes may include at least one probe capable of detecting, directly or indirectly, a marker disclosed herein associated with higher risk of developing LOAD and at least one other probe is capable of detecting, directly or indirectly, a marker disclosed herein associated with lower risk of developing LOAD.
The expression of the marker in a sample may be compared to a level of expression predetermined to predict the presence or absence of a particular physiological characteristic. The level of expression may be derived from a single control or a set of controls. A control may be any sample with a previously determined level of expression. A control may comprise material within the sample or material from sources other than the sample. Alternatively, the expression of a marker in a sample may be compared to a control that has a level of expression predetermined to signal or not signal a cellular or physiological characteristic. This level of expression may be derived from a single source of material including the sample itself or from a set of sources. Comparison of the expression of the marker in the sample to a particular level of expression results in a prediction that the sample exhibits or does not exhibit the cellular or physiological characteristic.
Prediction of a cellular or physiological characteristic includes the prediction of any cellular or physiological state that may be predicted by assessing the expression of a marker. Examples include the identity of a cell as a particular cell including a particular normal or diseased cell type, the likelihood that one or more diseases is present or absent, the likelihood that a present disease will progress, remain unchanged, or regress, the likelihood that a disease will respond or not respond to a particular therapy, or any other disease outcome. Further examples include the likelihood that a cell will move, senesce, apoptose, differentiate, metastasize, or change from any state to any other state or maintain its current state.
One type of cellular or physiological characteristic is the risk that a particular disease outcome will occur. Assessing this risk includes the performing of any type of test, assay, examination, result, readout, or interpretation that correlates with an increased or decreased probability that an individual has had, currently has, or will develop a particular disease, disorder, symptom, syndrome, or any condition related to health or bodily state. Examples of disease outcomes include, but need not be limited to survival, death, progression of existing disease, remission of existing disease, initiation of onset of a disease in an otherwise disease-free subject, or the continued lack of disease in a subject in which there has been a remission of disease. Assessing the risk of a particular disease encompasses diagnosis in which the type of disease afflicting a subject is determined. Assessing the risk of a disease outcome also encompasses the concept of prognosis. A prognosis may be any assessment of the risk of disease outcome in an individual in which a particular disease has been diagnosed. Assessing the risk further encompasses prediction of therapeutic response in which a treatment regimen is chosen based on the assessment. Assessing the risk also encompasses a prediction of overall survival after diagnosis.
Determining whether or not the presence of an allele signifies a physiological or cellular characteristic may be assessed by any of a number of methods. The skilled artisan will understand that numerous methods may be used to select a marker or a plurality of markers that signifies a particular physiological or cellular characteristic. In diagnosing the presence of a disease, a threshold value may be obtained by performing the assay method on samples obtained from a population of patients having a certain type of disease (Alzheimer's disease for example,) and from a second population of subjects that do not have the disease. In assessing disease outcome or the effect of treatment, a population of patients, all of which may develop a disease such as AD, may be followed for a period of time. After the period of time expires, the population may be divided into two or more groups. For example, the population may be divided into a first group of patients who did develop AD and a second group of patients who did not develop AD. Examples of endpoints include occurrence of one or more symptoms of disease, death, formation of neurofibrillary tangles, memory loss, or other states to which the given disease may progress. If presence of the marker in a sample statistically aligns with one group relative to the other group, the subject from which the sample was derived may be assigned a risk of having the same outcome as the patient group that differentially displays the marker.
Other methods may be used to assess how accurately the presence or absence of a marker signifies a particular physiological or cellular characteristic. Such methods include a positive likelihood ratio, negative likelihood ratio, odds ratio, and/or hazard ratio. In the case of a likelihood ratio, the likelihood that the presence or absence of the marker would be found in a sample with a particular cellular or physiological characteristic is compared with the likelihood that the presence or absence of the marker would be found in a sample lacking the particular cellular or physiological characteristic.
An odds ratio measures effect size and describes the amount of association or non-independence between two groups. An odds ratio is the ratio of the odds of a marker being present or absent in one set of samples versus the odds of the marker being present or absent in the other set of samples. An odds ratio of 1 indicates that the event or condition is equally likely to occur in both groups. An odds ratio grater or less than 1 indicates that presence or absence of the marker is more likely to occur in one group or the other depending on how the odds ratio calculation was set up.
A hazard ratio may be calculated by estimate of relative risk. Relative risk is the chance that a particular event will take place. It is a ratio of the probability that an event such as development or progression of a disease will occur in samples in which a particular marker is present over the probability that the event will occur in samples in which the particular marker is absent. Alternatively, a hazard ratio may be calculated by the limit of the number of events per unit time divided by the number at risk as the time interval decreases. In the case of a hazard ratio, a value of 1 indicates that the relative risk is equal in both the first and second groups; a value greater or less than 1 indicates that the risk is greater in one group or another, depending on the inputs into the calculation.
Detection of the disease also includes detection of the haplotype by any SNPs/markers within the haplotype, but also indirectly through SNPs/markers outside the haplotype and leveraging linkage disequilibrium to identify carriers of the haplotype. In addition to determining a patient's relative risk for LOAD, the diagnosis may include prescribing therapeutic regimens to treat, prevent or delay onset of LOAD.
The method of diagnosis will further include direct or indirect detection of APOE alleles associated with LOAD, preferably the APOE-ε4 allele. Such detection may be performed using any of the detection methods available to one of skill in the art and the markers disclosed herein and APOE alleles may be detected using the same or different methods and may be detected at the same or different times. Further, the method of diagnosis may rely upon the information regarding the APOE alleles of the subject that had been previously determined. With information regarding any marker disclosed herein and APOE alleles of a subject, the diagnosis of risk may be determined and present in the form of Odds Ratio (OR) or other estimates for the set of alleles possessed by the subject.
EXAMPLES
Elements and acts in the example are intended to illustrate the invention for the sake of simplicity and have not necessarily been rendered according to any particular sequence or embodiment.
Example 1
Identification of SNPs Associated with LOAD
Only 46% of haplotypic variation from the CEPH population of the human HapMap may be captured by the Affymetrix 500K Mapping Assay. As a result, discoverable odds ratios in this study ranged from 2.0 to as low as 1.1-1.3. Use of discoverable odds ratios in this range require a study with greater statistical power, and in turn larger sample sizes. As a result, a genome-wide association study was performed that uses the Affymetrix 6.0 Array which measures  ̃906,000 SNPs (representing 85-95% genomic coverage) and  ̃946,000 copy number variations (CNVs), with a discovery cohort of over 2900 samples.
Generally, this type of study presents challenges due to biologic and phenotypic heterogeneity. The pathology of AD may present as a dementia syndrome, as MCI, or be present in persons without cognitive impairment. Additionally, Alzheimer's dementia is frequently due to a combination of AD pathology in addition to other common age-related pathlogies (e.g., cerebral infarctions). A typical approach to this problem is to create large sample sizes in order to detect a small signal from background heterogeneity. Along with the large sample size, this study used neuropathologically verified cases and controls to further control heterogeneity. This study also used quantitative endophenotypes that capture the range of clinical status (e.g., level of and change in cognitive function) and the spectrum of neuropathology (e.g., quantitative measures of AD pathology). Thus, two of the additional cohorts used herein are longitudinal, epidemiologic clinical pathologic studies that include a wide range of quantitative data.
All samples were genotyped on the Affymetrix platform. Of those samples 400 were selected for genotyping on the Illumina platform. The selection of the 400 samples was based on the availability of whole genome expression data for these samples. Overall, the study performed genotyping analysis on about 2,600 subjects.
The samples were of three types: clinically diagnosed and neuropathologically confirmed LOAD cases and controls (approximately 2025 samples), neuropathologically characterized samples from a longitudinal epidemiological cohort (approximately 700 samples, some of which qualify as LOAD cases and controls), and antemortem samples from the Banner PET cohort from individuals genetically likely to develop AD (approximately 200 samples). The Rush cohort and PET cohort were used as two endophenotype replication cohorts.
The genotype results from each individual were imputed to increase the genome coverage and also to “clean” the data by re-calling each SNP according to the LD structure and genotype calls of the neighboring SNPs. Extending the SNP set from 1 million to 2.4 million SNPs also allowed for identification of loci with multiple significant SNPs rather than a single significant SNP.
Structure and principle components analysis was used to assess the extent of stratification and admixture in a set of 1,000 unlinked SNPs in each individual. The discovery set includes approximately 2025 LOAD cases (Braak and Braak score V or VI, Cerad B or C, clinical diagnosis of possible or probable Alzheimer's disease) and controls (Braak and Braak score I or II, Cerad 0 or A, no clinical diagnosis of dementia) from several independent cohorts. Power estimates for the discovery cohort are listed below:







TABLE 1







Power to detect effects in the discovery cohort


(alpha = 0.001, two-sided test, D > 0.7)










Disease




Allele
Allellic Odds Ratio












Frequency
1.3
1.2
1.1
















40%
100%
77%
22%



30%
99%
70%
18%



20%
97%
54%
12%



10%
77%
25%
5%



5%
37%
9%
2%



1%
9%
2%
1%










Analyses were performed through the use of the following strategies:

A. Single SNP Permutation Analyses

As the number of SNPs increases with denser platforms and imputation, the multiple testing considerations increase, particularly since imputed data sets contain up to 2.4 million SNPs Therefore, maxT permutation analyses was used to control for multiple tests rather than a Bonferroni or Sidak correction, which are likely overly conservative.
B. Quantitative Trait Analyses
Quantitative endophenotype information is available on a portion of the postmortem samples that were genotyped. This information includes data on Braak staging and CERAD plaque estimates. These measures may be analyzed as a quantitative trait against the SNP genotype data to predict SNPs that associate with specific features of LOAD.
C. Set-Association, ReliefF/MDR and Other Compound Analyses
The analyses described above resulted in the identification of several trait-associated SNPs and haplotypes irrespective of potential gene-gene interactions. A pattern of gene interactions was extracted through set-association analyses and other compound genetic analyses in collaboration with the investigators noted above. The level of complexity of the existing interactions was very high in this data set. Therefore, only convergent results from both methods were considered for further evaluation. Set-association evaluates several sets of polymorphic markers throughout the genome and results in a powerful single genome-wide test statistic (See Reference 11). It uses such relevant sources of information as allelic association and Hardy-Weinberg disequilibrium. This information is combined over multiple markers and genes in the genome, quality control is improved by trimming, and permutation tests limit the overall false-positive rate.
Hierarchical cluster analysis was used to allocate significant SNPs and haplotypes to coherent clusters. Among several proximity values and fusion algorithms the weighted average clustering (fusion algorithm) and the simple matching coefficient (proximity value) were selected. The simple matching coefficient is the most suitable proximity value in cases where the values of a binary variable have equal validity. The weighted average clustering (fusion algorithm) is a balanced clustering method, which can be used for every proximity value and is not prone to string formation. Neuman et al. provided evidence for the suitability of cluster analysis in real AD data sets (See Reference 12) and replicated all chromosomal regions formerly identified by using affected-sib-pair methods. While the χ2- and logistic regression-based analyses aim at identifying novel markers and molecular targets, the set-association and hierarchical cluster analyses will establish the optimal combination of polymorphic markers for diagnosis and, ultimately, prognosis of AD.
Validation of the SNPs listed in Table 2 may be performed using cohorts that have been genotyped, using imputation to test the SNPs. Alternatively, a custom array may be designed. Additionally, fine-mapping or sequencing of the regions around the selected SNPs may be used to identify and/or confirm mutations in coding regions.







TABLE 2







SNPs associated with LOAD










SNP
Chromosome
BP
Direct P Value













rs429358
19
50103781
4.77E−47


rs4420638
19
50114786
2.05E−45


rs1160985
19
50095252
9.81E−20


rs7412
19
50103919
3.72E−10


rs17042395
3
16568435
6.56E−08


rs16889006
5
20995156
2.55E−07


rs5981380
23
74791863
3.55E−07


rs11066247
12
111226194
4.57E−07


rs4533297
16
77994546
1.82E−06


rs6636980
23
142420716
2.22E−06


rs7895861
10
54057477
2.28E−06


rs6632813
23
16349702
2.50E−06


rs16834130
1
150731984
3.17E−06


rs264256
18
10921528
3.37E−06


rs11217627
11
119379644
4.54E−06


rs13417560
2
159733535
5.11E−06


rs13404031
2
159754694
6.34E−06


rs829465
6
72488174
6.71E−06


rs5955490
23
139369475
6.85E−06


rs1533822
16
26680632
7.12E−06


rs2500144
23
142948938
7.69E−06


rs3112160
2
38926825
7.83E−06


rs11676819
2
105653813
8.91E−06


rs8042680
15
89322341
1.02E−05


rs7908601
10
92925026
1.04E−05


rs40666
5
9281171
1.04E−05


rs9351848
6
72501745
1.09E−05


rs6631389
23
31703010
1.19E−05


rs642612
17
74033121
1.52E−05


rs13033552
2
123500876
1.69E−05


rs35306465
4
183306697
1.78E−05


rs13395944
2
105655085
1.79E−05


rs1204331
6
72500090
1.89E−05


rs9375555
6
128589687
2.12E−05


rs2058810
16
48516336
2.25E−05


rs1634508
17
31450358
2.36E−05


rs2127470
15
92451058
2.39E−05


rs10079121
5
9281649
2.50E−05


rs829467
6
72489698
2.63E−05


rs11097396
4
77659357
2.77E−05


rs10009946
4
63911889
2.79E−05


rs10783282
12
47433214
2.93E−05


rs670139
11
59728371
3.02E−05


rs7064361
23
57978804
3.08E−05


rs16950383
16
78006279
3.08E−05


rs6603530
23
118572567
3.10E−05


rs6709683
2
105677780
3.13E−05


rs4910821
11
5563215
3.19E−05


rs10400909
15
92450125
3.26E−05


rs847386
7
16941578
3.37E−05


rs12186632
5
114049116
3.71E−05


rs1256444
15
81337307
4.05E−05


rs182174
21
17502225
4.22E−05


rs1256428
15
81318872
4.32E−05


rs6094509
20
35438689
4.33E−05


rs5987025
23
153663006
4.44E−05


rs6865969
5
158435306
4.53E−05


rs4547126
11
5543590
4.62E−05


rs4843267
16
86357971
4.74E−05


rs10140673
14
94211685
4.78E−05


rs650943
11
59763341
5.14E−05


rs1130371
17
31440650
5.15E−05


rs3814127
9
128305563
5.15E−05


rs9332441
12
47357512
5.38E−05


rs1954850
11
101883770
5.54E−05


rs11038193
11
5561289
5.54E−05


rs10859338
12
91472788
5.55E−05


rs9784631
5
29361320
5.63E−05


rs6512077
19
15972223
5.85E−05


rs2541286
23
146541854
5.85E−05


rs1943229
18
56237438
6.20E−05


rs2286276
7
72625290
6.27E−05


rs10198042
2
105634020
6.29E−05


rs4286782
6
55431389
6.30E−05


rs7535789
1
24480006
6.31E−05


rs2881599
16
26677629
6.37E−05


rs676309
11
59758149
6.44E−05


rs6552910
4
186863802
6.53E−05


rs17494056
2
159760977
6.70E−05


rs853585
10
119844853
6.85E−05


rs17317101
23
113232500
7.10E−05


rs10504376
8
65543485
7.10E−05


rs10742722
11
5542948
7.21E−05


rs2250392
12
113458972
7.25E−05


rs2881458
15
84959696
7.32E−05


rs16931253
8
65547912
7.35E−05


rs17025061
2
100943912
7.39E−05


rs9309095
2
43088955
7.42E−05


rs4113946
12
47310287
7.61E−05


rs2827909
21
23442973
7.64E−05


rs9904820
17
43292446
7.89E−05


rs4972391
2
149204738
7.94E−05


rs1530914
11
59785516
7.97E−05


rs4794346
17
47862514
7.99E−05


rs11133822
5
15753541
8.20E−05


rs1009987
10
73337354
8.37E−05


rs5962536
23
104611145
8.37E−05


rs1359651
20
20706593
8.42E−05


rs10503040
18
56230239
8.45E−05


rs4090174
9
131190426
8.50E−05


rs17835266
11
89855586
8.52E−05


rs6983226
8
1944577
8.65E−05


rs17865911
4
118517807
8.65E−05


rs1582763
11
59778524
8.67E−05


rs7207413
17
28806787
8.72E−05


rs13013898
2
123512389
8.73E−05


rs1202525
1
229018521
8.79E−05


rs2033494
19
22392386
8.82E−05


rs2956581
5
36538618
9.02E−05


rs40665
5
9281283
9.05E−05


rs9435127
1
9190296
9.06E−05


rs4648858
1
24479146
9.43E−05


rs4648959
1
24476105
9.44E−05


rs1026254
11
59787033
9.63E−05


rs1350089
18
63151304
9.64E−05


rs10402271
19
50021054
9.67E−05


rs10742719
11
5542828
9.74E−05


rs2500153
23
142964425
9.92E−05


rs6817424
4
81217787
9.95E−05


rs466093
21
30188911
0.0001012


rs4746100
10
73339711
0.0001021


rs508915
18
41686356
0.0001028


rs7108663
11
59784718
0.0001033


rs6591559
11
59782141
0.0001037


rs12539316
7
72615834
0.0001039


rs2346709
15
84959609
0.0001057


rs10194269
2
105660325
0.0001057


rs5910606
23
118555812
0.0001071


rs17835397
11
89857625
0.0001081


rs4357331
8
1925405
0.0001092


rs2277365
12
47362078
0.0001094


rs17711743
16
77996536
0.0001095


rs11106228
12
90561550
0.0001099


rs41407844
4
81219977
0.0001108


rs2136342
13
75617791
0.0001109


rs3828191
2
165058148
0.000111


rs16951392
17
47845191
0.000112


rs1479831
15
92445234
0.000113


rs622920
13
43404671
0.0001142


rs4479297
17
47818557
0.0001183


rs11095608
23
13162923
0.0001184


rs5978287
23
8955187
0.0001186


rs9842566
3
16041190
0.0001188


rs953362
20
20701544
0.0001255


rs4289558
5
15788014
0.0001258


rs10512156
9
86713008
0.0001269


rs655231
11
59770433
0.0001279


rs4938931
11
59783189
0.0001281


rs12749061
1
62102345
0.0001282


rs12647148
4
60424911
0.0001294


rs1442063
18
49377940
0.0001317


rs4342343
5
29350811
0.0001317


rs4315367
17
72030753
0.000135


rs4794347
17
47862591
0.0001368


rs1019670
11
59697175
0.0001383


rs11954932
5
123874867
0.0001384


rs4984259
15
61365054
0.0001388


rs2001517
18
54293292
0.0001395


rs6039654
20
9945251
0.00014


rs1409428
20
20705815
0.0001414


rs17145817
7
72684715
0.0001416


rs2278583
2
42843096
0.0001431


rs16931273
8
65555877
0.0001444


rs6654877
23
8559261
0.0001448


rs2603779
3
16043588
0.0001457


rs7051342
23
107420389
0.000146


rs371298
23
118521354
0.0001463


rs12009590
23
150635183
0.000147


rs11698059
20
20714260
0.0001474


rs991110
14
60877898
0.0001478


rs4121392
11
100148633
0.0001481


rs2612600
8
65510460
0.0001496


rs1102617
21
17521369
0.0001502


rs949973
5
123881433
0.0001519


rs11655913
17
30821778
0.0001541


rs3912944
23
86236218
0.0001545


rs953363
20
20701683
0.0001566


rs9555552
13
108522077
0.0001573


rs3120733
23
154157260
0.0001574


rs6137147
20
20709015
0.0001583


rs1277307
4
57591456
0.0001584


rs10077548
5
123876716
0.0001601


rs10900908
6
1442522
0.0001604


rs5981711
23
74068338
0.000162


rs6726524
2
33612197
0.0001637


rs12781952
10
24741698
0.0001647


rs562028
11
59634426
0.000165


rs1026255
11
59786525
0.000166


rs17488034
13
26314251
0.0001674


rs5758223
22
39819866
0.0001674


rs891088
19
7135762
0.0001675


rs1945390
11
122025463
0.0001692


rs831480
6
37004806
0.00017


rs846814
9
122128253
0.0001715


rs12798784
11
89986271
0.0001718


rs7018850
9
4293517
0.000172


rs3813097
18
72337990
0.0001724


rs1377334
5
114295122
0.0001725


rs10869422
9
70659729
0.0001753


rs16852038
2
215148427
0.0001761


rs7161372
14
91866160
0.0001765


rs10426094
19
7156240
0.0001779


rs6473080
8
79098294
0.0001785


rs1123024
17
28799974
0.0001791


rs1618513
6
6477615
0.0001801


rs9434717
1
9190487
0.0001827


rs2827881
21
23427801
0.0001839


rs6914564
6
135445317
0.000185


rs3208856
19
49988646
0.0001881


rs12468287
2
146070764
0.0001902


rs11788891
9
128246019
0.0001911


rs4233036
1
24475382
0.0001918


rs1531347
18
48432144
0.0001944


rs12336107
9
4300558
0.0001944


rs1805957
5
9287736
0.0001964


rs9374351
6
113064907
0.0001984


rs4336923
10
20409004
0.0001993


rs10069190
5
123879549
0.0002017


rs4827479
23
65574614
0.000202


rs10897049
11
59857157
0.0002043


rs1883487
20
9353485
0.0002065


rs1409427
20
20702959
0.0002074


rs589605
23
144161283
0.0002088


rs5966049
23
145027730
0.0002102


rs4510072
17
28802549
0.0002146


rs4643583
2
56313685
0.0002169


rs4744768
9
77610062
0.0002172


rs2232313
23
129457754
0.0002181


rs1596039
18
46110711
0.0002184


rs4964586
12
106429621
0.0002188


rs6542225
2
115273275
0.000219


rs6705923
2
53037381
0.0002209


rs6551575
4
61216515
0.0002211


rs1752653
13
26220777
0.0002228


rs957979
17
31460821
0.0002232


rs4362707
3
16029235
0.0002278


rs2042922
5
29377058
0.0002281


rs41323947
1
74617191
0.0002298


rs820255
17
71102117
0.00023


rs7298828
12
90558991
0.000231


rs2252238
12
45228174
0.0002311


rs5910607
23
118555830
0.0002316


rs7824527
8
6877608
0.0002338


rs2398671
5
143081401
0.000234


rs1805952
5
9299599
0.0002356


rs1719141
17
31454563
0.0002383


rs2503285
6
104089558
0.0002384


rs2728524
3
2187318
0.0002386


rs10819162
9
128265359
0.0002415


rs1553497
17
28781096
0.0002421


rs6683441
1
217024728
0.0002433


rs1879818
8
141516084
0.0002433


rs8015610
14
94192101
0.000244


rs7579138
2
42838249
0.0002446


rs17137349
5
114369300
0.0002447


rs6724143
2
159693757
0.0002454


rs397118
23
96960172
0.0002461


rs12511743
4
189883970
0.0002469


rs1040211
15
90424674
0.0002496


rs2001217
15
89299250
0.0002509


rs12326462
18
41129825
0.0002515


rs17498815
12
100233988
0.0002516


rs10742725
11
5543121
0.000252


rs2224182
20
11521668
0.0002524


rs2834330
21
34288089
0.0002539


rs3745546
19
7162816
0.0002545


rs6535872
4
153936800
0.0002626


rs7249558
19
58481703
0.0002631


rs10514883
18
54271634
0.0002639


rs7243684
18
46160836
0.0002644


rs6577561
1
9197033
0.0002656


rs1256447
15
81339221
0.0002677


rs13382950
2
227664311
0.0002679


rs685859
1
180040894
0.0002701


rs2402961
7
129192917
0.0002709


rs5758267
22
39949296
0.0002711


rs17207648
2
159673112
0.0002718


rs10758597
9
4291782
0.0002727


rs2486027
10
125294541
0.0002739


rs2110706
14
88925487
0.0002757


rs2059129
5
143076857
0.0002757


rs11257695
10
12385446
0.0002796


rs4354335
8
114475512
0.0002799


rs16901211
5
11080918
0.0002809


rs10476994
5
151059242
0.0002826


rs4676320
2
107130693
0.0002832


rs11230180
11
59718062
0.0002837


rs10885864
10
117895695
0.0002851


rs11646101
16
17231085
0.000287


rs4576739
10
57931414
0.0002871


rs9807618
18
10676131
0.0002873


rs1155098
8
65490948
0.0002879


rs2043422
8
142305519
0.0002894


rs6677009
1
228973577
0.0002901


rs2960455
7
77359883
0.0002913


rs7868954
9
4879208
0.0002945


rs10066153
5
123883295
0.0002949


rs2090922
8
141515495
0.0002958


rs34661737
7
83453919
0.0002991


rs5910608
23
118556154
0.0003042


rs610352
11
59753544
0.0003057


rs943218
20
20715084
0.0003073


rs293540
20
30536829
0.0003094


rs2834341
21
34306691
0.0003106


rs7674035
4
36154894
0.0003106


rs10115578
9
3474373
0.0003109


rs13029092
2
167027829
0.0003133


rs9378774
6
327897
0.0003147


rs4283782
5
123883985
0.0003156


rs319858
2
115247311
0.0003182


rs2899683
15
60725461
0.0003186


rs7210605
17
47861956
0.0003189


rs805530
20
36507613
0.0003204


rs718376
11
59759511
0.0003225


rs7069106
10
92928879
0.000324


rs1021632
10
4642819
0.0003244


rs7734932
5
9281481
0.000325


rs2437803
15
84950790
0.0003276


rs717666
16
26692199
0.000328


rs13020250
2
118248034
0.0003282


rs1378169
3
15985616
0.0003291


rs11180553
12
74196574
0.0003302


rs10897003
11
59594153
0.0003305


rs8082463
17
47820437
0.0003316


rs10819174
9
128307886
0.0003325


rs11114028
12
107620076
0.0003327


rs12892914
14
59849637
0.000335


rs2577894
8
65524163
0.0003354


rs999939
2
85422805
0.0003357


rs4953706
2
43083413
0.0003366


rs10430148
1
24474160
0.0003381


rs9424093
10
10846395
0.0003414


rs7577837
2
146068506
0.0003467


rs2289711
12
27568772
0.000347


rs7947761
11
100129809
0.0003473


rs4794225
17
43312590
0.0003487


rs7876084
23
93516115
0.0003492


rs10069118
5
29375689
0.0003498


rs10062543
5
123876236
0.00035


rs7243917
18
12589042
0.0003528


rs11133030
4
175254410
0.000356


rs7872516
9
109025041
0.0003566


rs12555462
9
106757032
0.0003575


rs4961341
8
142304336
0.0003576


rs17522996
7
47351726
0.0003581


rs5951325
23
100596349
0.000359


rs4842993
15
81504446
0.0003601


rs12037869
1
85467574
0.0003602


rs2885856
2
84049495
0.0003614


rs293542
20
30539357
0.0003623


rs7849193
9
136790645
0.0003642


rs12685147
9
105212719
0.0003646


rs1372567
6
46437363
0.0003663


rs6022638
20
51706144
0.0003664


rs17650435
11
37013796
0.0003667


rs10504377
8
65555633
0.0003678


rs880293
14
94214129
0.0003679


rs12037204
1
115969319
0.0003691


rs687582
13
43405689
0.0003718


rs6675497
1
217024584
0.0003726


rs1566106
5
178278821
0.0003727


rs3104996
8
96632981
0.0003729


rs2234246
6
41351718
0.0003731


rs10188267
2
146069750
0.0003746


rs11079804
17
43375697
0.0003769


rs7106518
11
59596363
0.0003771


rs16841583
3
100853294
0.0003773


rs10820403
9
105045896
0.0003776


rs2495988
6
34065112
0.0003786


rs167602
11
5518171
0.0003787


rs1184766
3
2234929
0.0003787


rs7322229
13
104201563
0.0003797


rs4813394
20
20721090
0.0003802


rs16979301
23
13760577
0.0003811


rs3886569
11
89880510
0.0003819


rs8110666
19
13319662
0.000382


rs11073964
15
89344765
0.0003822


rs11889938
2
105622619
0.0003824


rs13037545
20
10060058
0.0003836


rs6716363
2
205642494
0.0003852


rs884771
15
35290221
0.0003878


rs2901098
10
117884107
0.0003889


rs7123220
11
122013373
0.0003889


rs4903240
14
74105330
0.0003911


rs1479560
5
76504154
0.0003938


rs8112746
19
14891118
0.0003941


rs2317481
23
95073148
0.0003943


rs1178520
3
2235434
0.0003953


rs1943783
11
101863317
0.0003992


rs13313001
1
230386834
0.0004018


rs9285657
5
143077331
0.0004029


rs7896662
10
52547036
0.0004034


rs2437801
15
84951181
0.0004034


rs2267346
22
35337416
0.0004063


rs3777530
6
89966276
0.0004065


rs9889183
16
26691736
0.0004093


rs1882569
7
70371814
0.000413


rs12499442
4
157379583
0.0004134


rs5763001
22
27866549
0.0004143


rs12632665
3
77852817
0.000415


rs1124166
4
120992581
0.0004181


rs1372254
2
141173140
0.0004183


rs1719220
17
31428390
0.0004205


rs9652691
16
80934452
0.0004219


rs6082159
20
20713237
0.0004225


rs1124165
4
120992522
0.0004245


rs17091212
14
94200283
0.0004258


rs7499241
16
77997040
0.0004284


rs42495
5
9284066
0.0004288


rs10194172
2
105660228
0.0004296


rs12617390
2
42838899
0.0004302


rs7031164
9
103645383
0.0004318


rs1997608
23
49326435
0.0004327


rs379717
5
88675886
0.0004332


rs17734389
2
211357028
0.0004367


rs6689572
1
207007565
0.0004368


rs4097545
9
4293313
0.0004384


rs1233078
5
154091321
0.0004385


rs10974859
9
4920487
0.0004386


rs8082787
18
21015369
0.00044


rs2110641
2
10208865
0.0004414


rs4903243
14
74113783
0.0004464


rs16964797
15
35283490
0.0004487


rs7250661
19
18829658
0.0004489


rs12909713
15
84946917
0.000449


rs7225545
17
47849828
0.0004504


rs2819190
1
63992338
0.0004529


rs617135
11
59693333
0.0004531


rs12628020
22
43857825
0.0004547


rs12006950
23
92974264
0.0004567


rs9896422
17
64377091
0.000461


rs7164426
15
84067909
0.0004616


rs2356132
2
8591035
0.0004616


rs17091265
14
94213701
0.0004666


rs10897020
11
59794143
0.0004741


rs805531
20
36508140
0.0004753


rs12809801
12
52922001
0.0004765


rs12444393
16
77998819
0.0004777


rs10511964
9
70577584
0.0004781


rs2081547
11
59746006
0.0004791


rs2809591
20
11711357
0.0004803


rs12606449
18
54303033
0.0004813


rs9427206
1
169203912
0.0004827


rs12652190
5
157125213
0.0004846


rs7694032
4
61235645
0.0004876


rs6075709
20
20709606
0.0004877


rs10758596
9
4291601
0.000488


rs4793734
17
43389104
0.0004897


rs17105491
10
125284396
0.0004898


rs17773314
5
6299957
0.0004921


rs10040520
5
29314106
0.0004932


rs6430090
2
146063929
0.0004936


rs4921744
8
17202683
0.0004962


rs17594509
4
45001935
0.0004979


rs293545
20
30542918
0.0004981


rs1108209
5
7900301
0.0004981


rs9405199
6
3353071
0.0005004


rs17253937
19
7135801
0.0005039


rs6621070
23
100595493
0.0005041


rs942950
10
131705664
0.0005052


rs5945088
23
100986203
0.0005054


rs11092309
23
100624381
0.0005058


rs17095429
11
100144512
0.0005076


rs2593529
2
167057716
0.0005076


rs10454797
4
142235623
0.0005086


rs2612589
8
65526999
0.00051


rs2827882
21
23428112
0.0005111


rs6594842
5
114202964
0.0005116


rs9369572
6
45766359
0.0005124


rs6479916
10
52520061
0.0005128


rs492496
11
51313877
0.0005147


rs1566430
5
165711472
0.0005149


rs12910825
15
89312264
0.0005156


rs6557512
6
157242759
0.0005157


rs13381188
18
49397848
0.0005165


rs4147047
13
41291824
0.0005166


rs10819173
9
128297367
0.0005167


rs12318549
12
129931121
0.0005178


rs200545
9
122137880
0.0005181


rs7580100
2
5197878
0.0005185


rs618499
11
107654049
0.0005191


rs2594953
8
59952764
0.0005205


rs7846493
8
136136037
0.0005217


rs1869620
4
187099677
0.0005228


rs7040120
9
70790991
0.0005241


rs667897
11
59693555
0.0005257


rs5756261
22
35338276
0.0005278


rs202869
21
17485166
0.0005281


rs846825
9
122133808
0.0005282


rs11049049
12
27609898
0.0005289


rs11106700
12
91713188
0.0005292


rs2430373
14
91464063
0.0005301


rs32425
5
50135571
0.0005304


rs10777410
12
91437062
0.0005309


rs17383755
5
114730035
0.0005333


rs6749325
2
10203917
0.0005334


rs9324521
8
136142833
0.0005341


rs7737490
5
112523988
0.0005345


rs6451453
5
39776837
0.0005376


rs7722665
5
157100881
0.0005382


rs17465431
2
123515886
0.0005389


rs2879724
4
157378249
0.0005389


rs2635296
4
118752075
0.0005406


rs4956509
4
142235877
0.0005413


rs4975725
5
2156059
0.0005418


rs6729547
2
159673406
0.0005423


rs6555483
5
7734207
0.0005436


rs541965
8
102703673
0.0005454


rs10121466
9
104797975
0.0005461


rs4861498
4
183306370
0.0005472


rs7871777
9
3519411
0.0005504


rs2479505
13
26228953
0.0005521


rs12659288
5
7755167
0.0005525


rs3829304
12
94588130
0.0005536


rs17098400
14
98745377
0.0005537


rs9494139
6
135456486
0.0005539


rs7215182
17
3665682
0.000554


rs7615639
3
43827569
0.0005583


rs7365975
1
230422758
0.0005585


rs1453013
5
114312438
0.0005591


rs3768235
1
85505962
0.0005592


rs11748700
5
15776346
0.0005619


rs673281
11
107687279
0.0005623


rs17332633
23
23324793
0.0005674


rs12107500
3
100848407
0.0005675


rs12658719
5
30379149
0.0005689


rs1467737
9
124022321
0.000569


rs7955859
12
26230998
0.0005704


rs8129151
21
15611653
0.0005713


rs11159907
14
88928501
0.0005741


rs11691971
2
140611862
0.0005744


rs7998410
13
43411260
0.0005787


rs6903671
6
157257433
0.0005789


rs5991907
23
100602061
0.000579


rs846818
9
122129840
0.00058


rs1009940
1
9200729
0.0005853


rs10790519
11
122040618
0.0005854


rs7648664
3
16007515
0.0005855


rs319855
2
115244200
0.0005856


rs2712590
12
44295788
0.000586


rs7625628
3
16010594
0.0005868


rs6828228
4
83197215
0.0005881


rs17039828
3
14590060
0.0005922


rs11752453
6
1439956
0.0005926


rs12375106
7
150194867
0.0005926


rs4514520
12
123274522
0.000593


rs10950254
7
70375143
0.0005935


rs1511556
3
147865826
0.0005946


rs8014761
14
94192236
0.0005947


rs2415025
15
66716850
0.0005949


rs4410671
5
121262937
0.0006046


AFFX-
1
63516479
0.0006053


SNP_65923_rs952998


rs4701641
5
15750062
0.0006058


rs1634507
17
31449687
0.0006069


rs10741175
10
130563773
0.0006082


rs6869793
5
114246813
0.0006101


rs7869556
9
18769533
0.0006107


rs4821990
22
39768656
0.0006138


rs293541
20
30539322
0.0006142


rs6603781
1
1148494
0.0006152


rs456298
21
41758621
0.0006156


rs2856044
3
60583127
0.0006158


rs5015994
14
41903194
0.0006159


rs10866514
5
15742507
0.0006167


rs11229192
11
54875843
0.000617


rs4844600
1
205745930
0.0006171


rs980793
5
39660837
0.0006175


rs12238307
9
3470671
0.0006178


rs4695895
4
175074462
0.0006206


rs824631
5
6498422
0.0006217


rs714235
20
11538160
0.0006225


rs9544313
13
76057418
0.0006233


rs11861905
16
17353902
0.0006256


rs11150971
18
72462172
0.0006271


rs1060455
19
43542270
0.000628


rs17135372
5
112532674
0.0006281


rs1352576
4
118739214
0.0006298


rs10878636
12
66301640
0.00063


rs6658884
1
116004334
0.0006305


rs2462645
7
47352947
0.0006306


rs9899379
17
15024206
0.0006327


rs9931815
16
26696066
0.000637


rs10036338
5
65745783
0.0006372


rs4861864
4
181841004
0.0006417


rs17091253
14
94213193
0.0006424


rs9485905
6
104478463
0.0006437


rs11239751
10
42540291
0.0006459


rs11872966
18
31019308
0.0006469


rs10825816
10
57952174
0.0006474


rs11778430
8
29027477
0.0006479


rs2649627
1
55770993
0.0006485


rs11671804
19
22383056
0.000649


rs7821916
8
136146848
0.0006497


rs3960965
19
58481195
0.0006499


rs16931257
8
65549902
0.0006525


rs252977
5
160663217
0.0006532


rs2204608
7
141278821
0.0006533


rs2653322
3
188771203
0.0006545


rs17712565
14
85123530
0.0006549


rs7026025
9
3469911
0.0006571


rs17117632
14
46315361
0.0006583


rs4257715
4
116830546
0.0006587


rs12408105
1
62084568
0.0006591


rs3786954
19
48964186
0.0006625


rs200547
9
122137243
0.0006656


rs12265862
10
42531656
0.0006664


rs275467
5
6891589
0.0006678


rs2455787
8
140555996
0.0006684


rs9654458
5
7721026
0.0006692


rs9964709
18
3295738
0.0006738


rs11694165
2
160903741
0.0006767


rs1416770
23
145026857
0.0006768


rs558514
3
171892753
0.0006799


rs1009947
3
60583757
0.000681


rs1823667
8
65527548
0.0006821


rs738977
22
35338874
0.0006848


rs1883488
20
9353752
0.0006864


rs1604382
12
74184709
0.000687


rs11241620
5
121252331
0.0006872


rs2136343
13
75617872
0.0006874


rs12800777
11
89866811
0.0006882


rs10037238
5
172642566
0.0006942


rs17598123
1
215095227
0.0006943


rs41437548
4
78918187
0.0006959


rs10519170
15
46473467
0.0006972


rs950027
15
43588327
0.0006982


rs7084466
10
10655422
0.0006983


rs3323
7
47365923
0.0007007


rs1798021
12
43022000
0.0007019


rs7199809
16
64585275
0.0007057


rs2812237
13
50197121
0.0007071


rs703374
10
119343808
0.0007074


rs2131361
4
83199857
0.0007092


rs1181913
7
155701605
0.0007104


rs4384677
18
54305444
0.0007112


rs16971511
17
74040865
0.0007128


rs7319447
13
41449508
0.0007131


rs4487976
1
24818242
0.0007135


rs7001207
8
96523919
0.0007135


rs713952
22
35338433
0.0007164


rs7070647
10
30141225
0.0007171


rs252272
16
29008903
0.0007173


rs17095426
11
100143813
0.0007174


rs9394781
6
41379106
0.0007199


rs2025466
10
10655967
0.0007203


rs7423892
2
161037890
0.0007204


rs10773829
12
129898052
0.000721


rs16983551
2
17426836
0.0007211


rs7061770
23
145017901
0.0007252


rs12342299
9
77832048
0.0007262


rs6796090
3
144793332
0.0007269


rs10825817
10
57953140
0.0007273


rs4694116
4
73163818
0.0007273


rs2304935
11
59858960
0.0007282


rs9651363
10
33169828
0.0007288


rs12127313
1
111655643
0.000729


rs848492
7
77395654
0.0007299


rs11016132
10
129908545
0.0007326


rs7495307
15
64939063
0.0007326


rs12648659
4
137324059
0.0007338


rs12495316
3
156533540
0.0007349


rs4393536
15
84940937
0.0007404


rs8057620
16
68442120
0.0007419


rs7316571
12
27629023
0.0007428


rs4237493
10
117884371
0.0007435


rs7666693
4
45634025
0.0007437


rs6770617
3
16011834
0.0007493


rs10515386
5
107685210
0.0007494


rs4701734
5
6509627
0.0007501


rs9395110
6
45761241
0.0007501


rs17255138
11
89916665
0.0007518


rs7071432
10
117899212
0.0007534


rs10477463
5
110554209
0.0007568


rs9812119
3
14588380
0.0007581


rs1256424
15
81321311
0.0007593


rs6546889
2
74171959
0.0007621


rs2694814
10
117866398
0.000763


rs10448254
9
122147729
0.0007648


rs5964670
23
67550826
0.0007654


rs10253781
7
30880636
0.0007662


rs10747215
18
73359436
0.0007669


rs3127080
10
115497312
0.0007703


rs10482042
23
87395545
0.0007717


rs2062368
11
133299698
0.0007724


rs6706570
2
10203817
0.0007733


rs298185
8
65467757
0.0007742


rs6562177
13
60890016
0.0007744


rs12818087
12
82287661
0.0007753


rs3755311
2
191554448
0.0007755


rs17771318
10
49581363
0.000776


rs7825534
8
96566190
0.0007795


rs6800857
3
186038304
0.0007806


rs6458458
6
45773675
0.0007819


rs394457
19
22022268
0.0007824


rs6997082
8
135903576
0.0007863


rs5935673
23
13793149
0.000787


rs2837995
21
41546340
0.0007879


rs9635948
18
43289577
0.0007905


rs7517283
1
23871196
0.0007935


rs1008055
8
140553899
0.0007939


rs1939194
11
87260772
0.0007945


rs35762589
2
53100421
0.0007974


rs13068144
3
172987423
0.0007978


rs1523314
3
2237692
0.0008012


rs10051640
5
114219275
0.000802


rs1366413
5
7731293
0.0008081


rs1149736
10
79648450
0.0008084


rs7031458
9
84710194
0.0008094


rs12595616
15
89364517
0.0008108


rs16830888
2
135138028
0.0008132


rs7679858
4
34978597
0.0008147


rs16863867
2
223124544
0.0008154


rs7018666
9
89652073
0.0008163


rs6861510
5
134606540
0.0008176


rs12446552
16
11627567
0.0008182


rs4562978
14
42542483
0.0008188


rs7152695
14
101459847
0.0008205


rs12601300
17
21082484
0.0008208


rs12922082
16
25786264
0.0008212


rs9872847
3
83010507
0.0008215


rs12191684
6
163991396
0.000822


rs10950253
7
70375023
0.0008225


rs3790971
1
228973398
0.0008231


rs158134
5
154339352
0.000824


rs7018692
9
70711601
0.0008247


rs11858967
15
84926556
0.0008256


rs7878331
23
102062093
0.0008269


rs10787629
10
117902194
0.0008304


rs4306376
13
106034515
0.0008319


rs10814235
9
3540086
0.0008327


rs3781533
10
117885629
0.0008348


rs16918465
8
110552472
0.0008354


rs1079022
11
45596304
0.0008387


rs4307374
8
136135317
0.0008398


rs1039147
4
91744589
0.0008416


rs17431
23
152709726
0.0008462


rs12440774
15
89283939
0.0008482


rs1519812
8
121114408
0.0008511


rs35775016
5
10141310
0.0008528


rs11237698
11
78435661
0.0008536


rs4771531
13
106032245
0.0008541


rs10799801
1
23877100
0.0008542


rs12692593
2
160905114
0.0008545


rs3019879
8
118086468
0.0008571


rs2019707
22
48055300
0.0008572


rs7044778
9
79466428
0.0008579


rs17034079
1
115972284
0.000858


rs12598082
16
17220789
0.0008607


rs10192963
2
105641096
0.0008705


rs10054011
5
38333961
0.0008707


rs2486866
10
7053222
0.0008717


rs2827879
21
23414584
0.0008749


rs10792084
11
54807466
0.0008764


rs7254358
19
7150341
0.0008769


rs4072688
10
23647331
0.0008786


rs802466
7
86165374
0.0008801


rs1395773
3
97958596
0.0008807


rs12632797
3
193577438
0.0008818


rs11741205
5
49941566
0.0008827


rs10515026
17
48205748
0.0008832


rs236573
17
65736802
0.0008838


rs11914999
3
110134703
0.0008841


rs6498220
16
11548039
0.0008847


rs40353
19
44571503
0.0008851


rs1959185
14
83182702
0.0008893


rs2273235
5
149887726
0.00089


rs9291171
4
73200490
0.0008935


rs17410182
4
79101107
0.000895


rs7595401
2
74117716
0.0008988


rs5907046
23
139533442
0.0008993


rs2166500
2
43022776
0.0009024


rs11647759
16
26694452
0.0009041


rs7297136
12
53264138
0.0009063


rs7532358
1
61893169
0.0009083


rs5992600
22
15831710
0.0009095


rs10792267
11
59858294
0.0009125


rs559664
11
69041441
0.0009132


rs1284059
18
13766822
0.0009134


rs10915495
1
3929593
0.0009161


rs1332249
9
122142868
0.0009173


rs9914336
17
67814383
0.0009188


rs11738432
5
157122196
0.0009193


rs1362729
18
23396044
0.0009201


rs16854702
2
168657480
0.0009205


rs16943700
17
55055363
0.0009216


rs7076076
10
73349651
0.0009224


rs17237607
3
126170122
0.0009228


rs16900667
8
126596016
0.0009246


rs13302146
9
105053258
0.0009266


rs4652931
1
37098670
0.0009279


rs9706460
12
45148787
0.0009286


rs10231253
7
157676114
0.0009294


rs1109916
1
230384567
0.0009295


rs9472557
6
45784786
0.0009311


rs2139615
2
176986713
0.0009326


rs4506675
11
59858169
0.0009329


rs1685513
3
2238690
0.0009358


rs7753479
6
153064844
0.0009359


rs6569979
6
135278851
0.0009367


rs2139109
2
105458724
0.0009378


rs6800578
3
144995427
0.0009382


rs17797399
16
77899455
0.0009384


rs1547329
13
21934103
0.0009444


rs2017823
18
2373523
0.000945


rs1460191
18
48435190
0.0009455


rs627178
1
40900563
0.0009455


rs17048072
4
116893093
0.0009467


rs12395571
23
87125037
0.0009469


rs17600575
4
163548786
0.0009477


rs2034085
15
89307456
0.0009494


rs16852953
1
202371798
0.0009499


rs1772988
6
2457119
0.0009511


rs41390747
4
116842242
0.0009512


rs10733121
1
236705735
0.000953


rs9267135
6
31545596
0.0009539


rs1881441
17
55053802
0.000954


rs2834344
21
34312918
0.0009575


rs11133602
5
10157640
0.000958


rs16959238
17
61849811
0.0009593


rs7290458
22
39806283
0.0009613


rs9909601
17
30841535
0.0009617


rs4241009
1
141510591
0.0009627


rs2242945
21
39389293
0.0009629


rs10974449
9
4301035
0.0009659


rs4898872
14
55287379
0.0009665


rs11629688
15
52771380
0.0009697


rs9652690
16
80934409
0.0009708


rs13053558
22
18061827
0.000971


rs16863859
1
169187683
0.0009721


rs552409
11
56326588
0.0009724


rs12686342
9
105216557
0.0009726


rs16914456
12
18712672
0.0009736


rs3913840
18
4436168
0.0009797


rs10988348
9
131192369
0.0009801


rs4382847
10
52236981
0.0009805


rs12316258
12
26230484
0.0009806


rs624761
1
18917464
0.0009824


rs10945913
6
163986705
0.0009827


rs914593
9
122210031
0.0009828


rs12196957
6
2474780
0.0009856


rs9520114
13
106045240
0.0009863


rs1993471
15
58827317
0.0009863


rs17643262
19
50323656
0.0009874


rs1537989
9
128281645
0.0009874


rs3822459
5
39427301
0.0009889


rs11584403
1
153011655
0.0009954


rs7148564
14
22893753
0.000996


rs41447448
1
115992668
0.0009995


rs2827911
21
23443694
0.001


rs2288522
19
60400287
0.001002


rs7120207
11
98486432
0.001004


rs2152649
9
70726326
0.001004


rs10267678
7
30894507
0.001005


rs11170973
12
53251464
0.001006


rs9776031
9
105068478
0.001007


rs11218016
11
120199964
0.001009


rs12969851
18
58105791
0.001009


rs16879693
8
110596605
0.001009


rs227103
1
69914136
0.00101


rs12313149
12
100108354
0.001013


rs1918676
18
10751757
0.001013


rs1471994
3
76197670
0.001014


rs1805960
5
9268331
0.001014


rs1417032
10
7052468
0.001015


rs958935
3
113753102
0.001015


rs4862558
4
186829632
0.001016


rs1111218
16
64602993
0.001017


rs614013
11
123697134
0.001018


rs3118077
13
50200311
0.001018


rs12084240
1
23853039
0.001022


rs4743641
9
105107354
0.001024


rs11710973
3
55192552
0.001025


rs252950
5
160647177
0.001025


rs41381844
5
110683591
0.001025


rs4537793
11
117558366
0.00103


rs7220146
17
55081473
0.001031


rs4369216
1
229264955
0.001033


rs7773435
6
1282034
0.001037


rs853389
6
14298744
0.001038


rs5956359
23
120693513
0.001039


rs10892873
11
122040543
0.00104


rs2181987
14
60887286
0.001041


rs7856017
9
29942326
0.001041


rs802441
7
86125039
0.001042


rs7197825
16
64590533
0.001043


rs17087898
9
86743031
0.001044


rs10515029
17
48243948
0.001045


rs9812150
3
134104645
0.001046


rs2213369
23
100906897
0.001047


rs7212136
17
22593769
0.00105


rs1719210
17
31460104
0.001051


rs10773890
12
130421426
0.001053


rs971354
4
46797872
0.00106


rs1081900
3
120034411
0.001062


rs217034
7
140652473
0.001062


rs16995332
20
1500457
0.001063


rs4978968
9
112734176
0.001063


rs9999758
4
135959118
0.001066


rs9898218
17
43461633
0.001067


rs9651104
1
212070341
0.001067


rs2031183
13
112905688
0.001068


rs1966374
4
15523132
0.001068


rs9504837
6
6473946
0.001068


rs1023964
2
146076321
0.001071


rs2398485
12
128843148
0.001072


rs17654608
4
53878489
0.001072


rs783376
6
117548067
0.001072


rs11143837
9
76014104
0.001072


rs10848219
12
129898081
0.001073


rs2203432
2
98801190
0.001073


rs17133758
11
98916596
0.001074


rs10031360
4
126958283
0.001075


rs2900285
9
132075459
0.001075


rs2040507
16
71581088
0.001077


rs1939184
11
87266534
0.00108


rs12513052
4
181646595
0.001081


rs2057915
7
140653479
0.001081


rs12294703
11
27190421
0.001084


rs2447265
15
84954786
0.001084


rs865671
6
14735136
0.001084


rs1346440
5
134600906
0.001085


rs16879230
7
33765580
0.001086


rs4421130
5
36617671
0.001087


rs7606424
2
176986683
0.001088


rs17236661
4
77415500
0.00109


rs4829946
23
137800274
0.001092


AFFX-
11
59713668
0.001095


SNP_9234256_rs636147


rs11947861
4
189873341
0.001096


rs7726558
5
118940497
0.001096


rs890731
5
134602305
0.001098


rs7699718
4
79098485
0.001099


rs9329143
5
177698849
0.001099


rs12225299
11
59841041
0.001103


rs4864737
4
53797470
0.001103


rs10110144
8
121074896
0.001103


rs8070132
17
55144988
0.001104


rs4961257
8
142301886
0.001105


rs2624938
6
2474303
0.001106


rs4955753
3
171962804
0.001107


rs4555926
6
153061594
0.001107


rs4978970
9
112737852
0.001112


rs7190355
16
64601406
0.001114


rs298069
5
59013969
0.001114


rs759112
23
36748565
0.001116


rs321325
6
45785076
0.001119


rs7086393
10
57920476
0.001122


rs1478281
8
4477685
0.001123


rs7084673
10
94157067
0.001124


rs8006542
14
88733952
0.001131


rs7603548
2
43018651
0.001132


rs4875330
8
4164349
0.001132


rs1002261
9
86756127
0.001136


rs16864008
2
223266030
0.001138


rs11133248
4
53752859
0.001138


rs7082405
10
608841
0.001142


rs17599877
5
126216415
0.001142


rs2954892
8
114552699
0.001143


rs28515995
23
135648246
0.001145


rs4699882
5
65944332
0.001148


rs17056952
9
73341612
0.001148


rs10198317
2
53807627
0.001149


rs2833325
21
31470453
0.00115


rs3104993
8
96641338
0.00115


rs1393360
3
79931615
0.001151


rs12829992
12
96604014
0.001155


rs7294982
12
44290428
0.001158


rs7517009
1
204082615
0.001163


rs7702491
5
8050545
0.001163


rs2160491
16
47603070
0.001164


rs6577853
8
135890845
0.001164


rs6123167
20
35990953
0.001168


rs4272222
6
53857633
0.001168


rs2382492
9
14621836
0.001169


rs7203844
16
47606386
0.00117


rs9390645
6
149317560
0.00117


rs1540125
11
78147371
0.001174


rs17602572
11
59704950
0.001175


rs11266413
23
78430327
0.001177


rs4639843
10
12389096
0.001178


rs2544081
12
44301754
0.001178


rs12123186
1
236969721
0.001178


rs2997967
1
235667890
0.001179


rs641118
1
180054971
0.001181


rs4898337
23
101288908
0.001182


rs9780606
23
149072768
0.001182


rs6966132
7
24866686
0.001182


rs4316805
17
29063736
0.001183


rs9376083
6
135393413
0.001185


rs17016207
4
143624532
0.001186


rs35393495
8
13091178
0.001186


rs7196364
16
7411668
0.001187


rs16857593
2
11593040
0.001187


rs2880301
13
18998534
9.27E−11


rs7412
19
50103919
3.72E−10


rs12741415
1
200741397
2.49E−09


rs1778596
1
143702635
4.46E−09


rs12723357
1
241185135
5.61E−09


rs17042395
3
16568435
6.56E−08


rs10199416
2
143462845
7.69E−08


rs429358
19
50103781
4.77E−47


rs2898441
21
41528394
0.04743


rs4420638
19
50114786
2.05E−45









In all SNPs shown in Table 2, the association is in reference to the minor allele in the Caucasian population.
Example 2
Identification of an Allele Associated with Reduced Risk of LOAD
Numerous SNPs on each chromosome of the human genome have been found to be associated with LOAD. The rs17042395 SNP on chromosome 3 was found to be significantly associated with altered Alzheimer's disease (AD) risk in the APOE E3/E3 group. These individuals are homozygous for the neutral form of the APOE risk allele. APOE is the strongest most replicated AD risk locus. Thus as determined during development of the present invention, when risk at the APOE locus is controlled for, a significant (surviving genome-wide hypothesis correction) association with altered AD risk at this SNP is observed. Remarkably, this SNP survives multiple hypothesis correction.

    P-value (logistic regression): 2.72E-08
    Odds Ratio=0.4045 (for the A-allele)
    Location: Chr. 3, BP 16568435
    SNP ID: rs17042395


The sequence surrounding rs17042395 SNP is set forth as SEQ ID NO:1 with R=A or G:







The sequence surrounding rs17042395 SNP is set


forth as SEQ ID NO: 1 with R = A or G:


AAAGAAAGGG GAAAGAAAAG GTATATTTGA AATGGAGACA


 


TAGCCCAAGG CTCTTAAACT CAGGGTTATG TCAGTCATGA


 


TGTAATAAAA TCATGAGGCC CTACATATAT TGTTTTTCTC


 


CTTTTGGTAT AAGCTTGGGT TTCAGAGCCA TGTTTTTCGA


 


CGCCAGTAAA ACTTCCAGCA CTAGCATGGA AATGAACTGC


 


AGTCGATGGC TGCCCTCAAG GTTGGAGAGG GGATAGGAAA


 


CTGGGGCTGC


 


R


TTGAACTGGA CAACACTTGT CTGGTCTCAG GTGGATGACT


 


GGTGTCAGCC CAGAATGGCC AGGAGGTGTG GCAAGATTTT


 


CCTGTTTGCC TAAAGAAAGT AACCACTTGG GATCTCCTGC


 


TTGTAAATGT TGGCCCAAGT TTTTGAACTC TACAGGGGCT


 


AAAGAAATCA TCCCCGAGGA CTGAGTTCAG CTTGTGGGTC


 


TCCAGCTTGC GCTCTCTGCT GTTCATTGCT ATAGTCTTGC


 


AAGAAGGTGG.


 


The “A” allele of rs17042395 (SEQ ID NO: 2):


GAGAGGGGATAGGAAACTGGGGCTGCATTGAACTGGACAACACTTGTCT


 


GGT.


 


The “G” allele of rs17042395 (SEQ ID NO: 3):


GAGAGGGGATAGGAAACTGGGGCTGCGTTGAACTGGACAACACTTGTCT


 


GGT.






Accordingly, this SNP is useful for diagnostic applications in non-carriers of the APOE risk allele (E4 allele). The rs17042395 SNP does not lie directly within any known gene in the human genome. Neighboring genes include RFTN1, DAZL, and an uncharacterized transcript, BC034913. Thus, these three genes represent novel targets for AD, especially for individuals that do not carry the APOE E4 risk allele.
REFERENCES
The references cited herein are expressly incorporated by reference to the extent allowed, as well as all of the following materials.

    1. Ritchie K and Kildea D, Lancet 346, 931-94 (1995).
    2. Gatz M et al, J Gerontol A Biol Sci Med Sci 52, M117-M125 (1997).
    3. Ashford J W and Mortimer J A, J Alzheimers Dis 4, 169-177 (2002).
    4. Tanzi R E, and Bertram L. Neuron 32, 181-184 (2001).
    5. Zubenko G S et al, Genomics 50, 121-128 (1998).
    6. Kehoe P et al, Hum Mol Genet 8, 237-245 (1999).
    7. Myers A et al, Am J Med Genet 114, 235-244 (2002).
    8. Risch N and Merikangas K, Science 273, 1516-1517 (1996).
    9. Coon K D et al, J Clin Psychiatry 68, 613-618 (2007).
    10. Reiman E M et al, Neuron. 54, 713-720 (2007).
    11. Hoh J et al, Genome Res 11, 2115-2119 (2001).
    12. Neuman R J et al, Genet Epidemiol 19, S57-63 (2000).

## Claims

1. A method of classifying a subject to a late onset Alzheimer's disease (LOAD) risk group, comprising:
receiving a sample from the subject;
detecting a first marker selected from the group consisting of rs10009946, rs1002261, rs10031360, rs10036338, rs10037238, rs10040520, rs10051640, rs10054011, rs10062543, rs10066153, rs10069118, rs10069190, rs10077548, rs10079121, rs1008055, rs1009940, rs1009947, rs1009987, rs10110144, rs10115578, rs10121466, rs10140673, rs10188267, rs10192963, rs10194172, rs10194269, rs1019670, rs10198042, rs10198317, rs10199416, rs1021632, rs10231253, rs1023964, rs10253781, rs1026254, rs1026255, rs10267678, rs1039147, rs10400909, rs1040211, rs10402271, rs10426094, rs10430148, rs10448254, rs10454797, rs10476994, rs10477463, rs10482042, rs10503040, rs10504376, rs10504377, rs10511964, rs10512156, rs10514883, rs10515026, rs10515029, rs10515386, rs10519170, rs1060455, rs10733121, rs10741175, rs10742719, rs10742722, rs10742725, rs10747215, rs10758596, rs10758597, rs10773829, rs10773890, rs10777410, rs10783282, rs10787629, rs1079022, rs10790519, rs10792084, rs10792267, rs10799801, rs10814235, rs1081900, rs10819162, rs10819173, rs10819174, rs10820403, rs10825816, rs10825817, rs10848219, rs10859338, rs10866514, rs10869422, rs10878636, rs10885864, rs10892873, rs10897003, rs10897020, rs10897049, rs10900908, rs10915495, rs10945913, rs10950253, rs10950254, rs10974449, rs10974859, rs10988348, rs11016132, rs1102617, rs11038193, rs11049049, rs11066247, rs11073964, rs11079804, rs1108209, rs11092309, rs11095608, rs11097396, rs1109916, rs11106228, rs11106700, rs1111218, rs11114028, rs11133030, rs11133248, rs11133602, rs11133822, rs11143837, rs11150971, rs11159907, rs11170973, rs11180553, rs11217627, rs11218016, rs11229192, rs11230180, rs1123024, rs11237698, rs11239751, rs11241620, rs1124165, rs1124166, rs11257695, rs11266413, rs1130371, rs1149736, rs1155098, rs11584403, rs1160985, rs11629688, rs11646101, rs11647759, rs11655913, rs11671804, rs11676819, rs11691971, rs11694165, rs11698059, rs11710973, rs11738432, rs11741205, rs11748700, rs11752453, rs11778430, rs1178520, rs11788891, rs1181913, rs1184766, rs11858967, rs11861905, rs11872966, rs11889938, rs11914999, rs11947861, rs11954932, rs12006950, rs12009590, rs1202525, rs12037204, rs12037869, rs1204331, rs12084240, rs12107500, rs12123186, rs12127313, rs12186632, rs12191684, rs12196957, rs12225299, rs12238307, rs12265862, rs12294703, rs12313149, rs12316258, rs12318549, rs12326462, rs1233078, rs12336107, rs12342299, rs12375106, rs12395571, rs12408105, rs12440774, rs12444393, rs12446552, rs12468287, rs12495316, rs12499442, rs12511743, rs12513052, rs12539316, rs12555462, rs1256424, rs1256428, rs1256444, rs1256447, rs12595616, rs12598082, rs12601300, rs12606449, rs12617390, rs12628020, rs12632665, rs12632797, rs12647148, rs12648659, rs12652190, rs12658719, rs12659288, rs12685147, rs12686342, rs12692593, rs12723357, rs12741415, rs12749061, rs1277307, rs12781952, rs12798784, rs12800777, rs12809801, rs12818087, rs12829992, rs1284059, rs12892914, rs12909713, rs12910825, rs12922082, rs12969851, rs13013898, rs13020250, rs13029092, rs13033552, rs13037545, rs13053558, rs13068144, rs13302146, rs13313001, rs1332249, rs13381188, rs13382950, rs13395944, rs13404031, rs13417560, rs1346440, rs1350089, rs1352576, rs1359651, rs1362729, rs1366413, rs1372254, rs1372567, rs1377334, rs1378169, rs1393360, rs1395773, rs1409427, rs1409428, rs1416770, rs1417032, rs1442063, rs1453013, rs1460191, rs1467737, rs1471994, rs1478281, rs1479560, rs1479831, rs1511556, rs1519812, rs1523314, rs1530914, rs1531347, rs1533822, rs1537989, rs1540125, rs1547329, rs1553497, rs1566106, rs1566430, rs158134, rs1582763, rs1596039, rs1604382, rs1618513, rs1634507, rs1634508, rs167602, rs16830888, rs16834130, rs16841583, rs16852038, rs16852953, rs16854702, rs1685513, rs16857593, rs16863859, rs16863867, rs16864008, rs16879230, rs16879693, rs16889006, rs16900667, rs16901211, rs16914456, rs16918465, rs16931253, rs16931257, rs16931273, rs16943700, rs16950383, rs16951392, rs16959238, rs16964797, rs16971511, rs16979301, rs16983551, rs16995332, rs17016207, rs17025061, rs17034079, rs17039828, rs17042395, rs17048072, rs17056952, rs17087898, rs17091212, rs17091253, rs17091265, rs17095426, rs17095429, rs17098400, rs17105491, rs17117632, rs17133758, rs17135372, rs17137349, rs17145817, rs1719141, rs1719210, rs1719220, rs17207648, rs17236661, rs17237607, rs17253937, rs17255138, rs17317101, rs17332633, rs17383755, rs17410182, rs17431, rs17465431, rs17488034, rs17494056, rs17498815, rs17522996, rs1752653, rs17594509, rs17598123, rs17599877, rs17600575, rs17602572, rs17643262, rs17650435, rs17654608, rs17711743, rs17712565, rs1772988, rs17734389, rs17771318, rs17773314, rs1778596, rs17797399, rs17835266, rs17835397, rs17865911, rs1798021, rs1805952, rs1805957, rs1805960, rs182174, rs1823667, rs1869620, rs1879818, rs1881441, rs1882569, rs1883487, rs1883488, rs1918676, rs1939184, rs1939194, rs1943229, rs1943783, rs1945390, rs1954850, rs1959185, rs1966374, rs1993471, rs1997608, rs2001217, rs2001517, rs200545, rs200547, rs2017823, rs2019707, rs2025466, rs202869, rs2031183, rs2033494, rs2034085, rs2040507, rs2042922, rs2043422, rs2057915, rs2058810, rs2059129, rs2062368, rs2081547, rs2090922, rs2110641, rs2110706, rs2127470, rs2131361, rs2136342, rs2136343, rs2139109, rs2139615, rs2152649, rs2160491, rs2166500, rs217034, rs2181987, rs2203432, rs2204608, rs2213369, rs2224182, rs2232313, rs2234246, rs2242945, rs2250392, rs2252238, rs2267346, rs227103, rs2273235, rs2277365, rs2278583, rs2286276, rs2288522, rs2289711, rs2304935, rs2317481, rs2346709, rs2356132, rs236573, rs2382492, rs2398485, rs2398671, rs2402961, rs2415025, rs2430373, rs2437801, rs2437803, rs2447265, rs2455787, rs2462645, rs2479505, rs2486027, rs2486866, rs2495988, rs2500144, rs2500153, rs2503285, rs252272, rs252950, rs252977, rs2541286, rs2544081, rs2577894, rs2593529, rs2594953, rs2603779, rs2612589, rs2612600, rs2624938, rs2635296, rs264256, rs2649627, rs2653322, rs2694814, rs2712590, rs2728524, rs275467, rs2809591, rs2812237, rs2819190, rs2827879, rs2827881, rs2827882, rs2827909, rs2827911, rs2833325, rs2834330, rs2834341, rs2834344, rs2837995, rs28515995, rs2856044, rs2879724, rs2880301, rs2881458, rs2881599, rs2885856, rs2898441, rs2899683, rs2900285, rs2901098, rs293540, rs293541, rs293542, rs293545, rs2954892, rs2956581, rs2960455, rs298069, rs298185, rs2997967, rs3019879, rs3104993, rs3104996, rs3112160, rs3118077, rs3120733, rs3127080, rs319855, rs319858, rs3208856, rs321325, rs32425, rs3323, rs34661737, rs35306465, rs35393495, rs35762589, rs35775016, rs371298, rs3745546, rs3755311, rs3768235, rs3777530, rs3781533, rs3786954, rs3790971, rs379717, rs3813097, rs3814127, rs3822459, rs3828191, rs3829304, rs3886569, rs3912944, rs3913840, rs394457, rs3960965, rs397118, rs40353, rs40665, rs40666, rs4072688, rs4090174, rs4097545, rs4113946, rs4121392, rs41323947, rs41381844, rs41390747, rs41407844, rs41437548, rs41447448, rs4147047, rs4233036, rs4237493, rs4241009, rs42495, rs4257715, rs4272222, rs4283782, rs4286782, rs4289558, rs4306376, rs4307374, rs4315367, rs4316805, rs4336923, rs4342343, rs4354335, rs4357331, rs4362707, rs4369216, rs4382847, rs4384677, rs4393536, rs4410671, rs4420638, rs4421130, rs4479297, rs4487976, rs4506675, rs4510072, rs4514520, rs4533297, rs4537793, rs4547126, rs4555926, rs4562978, rs456298, rs4576739, rs4639843, rs4643583, rs4648858, rs4648959, rs4652931, rs466093, rs4676320, rs4694116, rs4695895, rs4699882, rs4701641, rs4701734, rs4743641, rs4744768, rs4746100, rs4771531, rs4793734, rs4794225, rs4794346, rs4794347, rs4813394, rs4821990, rs4827479, rs4829946, rs4842993, rs4843267, rs4844600, rs4861498, rs4861864, rs4862558, rs4864737, rs4875330, rs4898337, rs4898872, rs4903240, rs4903243, rs4910821, rs4921744, rs492496, rs4938931, rs4953706, rs4955753, rs4956509, rs4961257, rs4961341, rs4964586, rs4972391, rs4975725, rs4978968, rs4978970, rs4984259, rs5015994, rs508915, rs541965, rs552409, rs558514, rs559664, rs562028, rs5756261, rs5758223, rs5758267, rs5763001, rs589605, rs5907046, rs5910606, rs5910607, rs5910608, rs5935673, rs5945088, rs5951325, rs5955490, rs5956359, rs5962536, rs5964670, rs5966049, rs5978287, rs5981380, rs5981711, rs5987025, rs5991907, rs5992600, rs6022638, rs6039654, rs6075709, rs6082159, rs6094509, rs610352, rs6123167, rs6137147, rs614013, rs617135, rs618499, rs622920, rs624761, rs627178, rs641118, rs642612, rs6430090, rs6451453, rs6458458, rs6473080, rs6479916, rs6498220, rs650943, rs6512077, rs6535872, rs6542225, rs6546889, rs6551575, rs655231, rs6552910, rs6555483, rs6557512, rs6562177, rs6569979, rs6577561, rs6577853, rs6591559, rs6594842, rs6603530, rs6603781, rs6621070, rs6631389, rs6632813, rs6636980, rs6654877, rs6658884, rs6675497, rs6677009, rs667897, rs6683441, rs6689572, rs670139, rs6705923, rs6706570, rs6709683, rs6716363, rs6724143, rs6726524, rs6729547, rs673281, rs6749325, rs676309, rs6770617, rs6796090, rs6800578, rs6800857, rs6817424, rs6828228, rs685859, rs6861510, rs6865969, rs6869793, rs687582, rs6903671, rs6914564, rs6966132, rs6983226, rs6997082, rs7001207, rs7018666, rs7018692, rs7018850, rs7026025, rs7031164, rs7031458, rs703374, rs7040120, rs7044778, rs7051342, rs7061770, rs7064361, rs7069106, rs7070647, rs7071432, rs7076076, rs7082405, rs7084466, rs7084673, rs7086393, rs7106518, rs7108663, rs7120207, rs7123220, rs713952, rs714235, rs7148564, rs7152695, rs7161372, rs7164426, rs717666, rs718376, rs7190355, rs7196364, rs7197825, rs7199809, rs7203844, rs7207413, rs7210605, rs7212136, rs7215182, rs7220146, rs7225545, rs7243684, rs7243917, rs7249558, rs7250661, rs7254358, rs7290458, rs7294982, rs7297136, rs7298828, rs7316571, rs7319447, rs7322229, rs7365975, rs738977, rs7423892, rs7495307, rs7499241, rs7517009, rs7517283, rs7532358, rs7535789, rs7577837, rs7579138, rs7580100, rs759112, rs7595401, rs7603548, rs7606424, rs7615639, rs7625628, rs7648664, rs7666693, rs7674035, rs7679858, rs7694032, rs7699718, rs7702491, rs7722665, rs7726558, rs7734932, rs7737490, rs7753479, rs7773435, rs7821916, rs7824527, rs7825534, rs783376, rs7846493, rs7849193, rs7856017, rs7868954, rs7869556, rs7871777, rs7872516, rs7876084, rs7878331, rs7895861, rs7896662, rs7908601, rs7947761, rs7955859, rs7998410, rs8006542, rs8014761, rs8015610, rs802441, rs802466, rs8042680, rs805530, rs805531, rs8057620, rs8070132, rs8082463, rs8082787, rs8110666, rs8112746, rs8129151, rs820255, rs824631, rs829465, rs829467, rs831480, rs846814, rs846818, rs846825, rs847386, rs848492, rs853389, rs853585, rs865671, rs880293, rs884771, rs890731, rs891088, rs914593, rs9267135, rs9285657, rs9291171, rs9309095, rs9324521, rs9329143, rs9332441, rs9351848, rs9369572, rs9374351, rs9375555, rs9376083, rs9378774, rs9390645, rs9394781, rs9395110, rs9405199, rs9424093, rs9427206, rs942950, rs943218, rs9434717, rs9435127, rs9472557, rs9485905, rs9494139, rs949973, rs950027, rs9504837, rs9520114, rs953362, rs953363, rs9544313, rs9555552, rs957979, rs958935, rs9635948, rs9651104, rs9651363, rs9652690, rs9652691, rs9654458, rs9706460, rs971354, rs9776031, rs9780606, rs9784631, rs9807618, rs980793, rs9812119, rs9812150, rs9842566, rs9872847, rs9889183, rs9896422, rs9898218, rs9899379, rs9904820, rs9909601, rs991110, rs9914336, rs9931815, rs9964709, rs999939, and rs9999758;
detecting a second marker consisting of an E3 allele of APOE;
classifying the subject into a risk group based upon the presence or absence of the markers; and
wherein detection of the first marker is provided by a first probe and detection of the second marker is provided by a second probe, and further wherein the first probe and the second probe are affixed to a solid support of a microarray.

2. The method of claim 1, further comprising isolating nucleic acid from the sample.

3. The method of claim 1, wherein the markers are detected directly.

4. The method of claim 3, wherein the detecting the markers further comprises a method selected from the group consisting of microarray analysis of genomic DNA with a gene chip and comparative genomic hybridization.

5. The method of claim 1, wherein the markers are associated with a low risk of developing LOAD and the subject is classified to a risk group with low risk of LOAD if the marker is detected in the sample.

6. The method of claim 5, wherein the first marker is the A allele of rs17042395.

7. The method of claim 6, wherein the subject is further classified based on the presence of two copies of the APOE-e3 allele.

8. A set of molecular probes used in assessing the risk of developing late onset Alzheimer's disease (LOAD) comprising:
a first probe capable of detecting a first SNP selected from a group consisting of rs10009946, rs1002261, rs10031360, rs10036338, rs10037238, rs10040520, rs10051640, rs10054011, rs10062543, rs10066153, rs10069118, rs10069190, rs10077548, rs10079121, rs1008055, rs1009940, rs1009947, rs1009987, rs10110144, rs10115578, rs10121466, rs10140673, rs10188267, rs10192963, rs10194172, rs10194269, rs1019670, rs10198042, rs10198317, rs10199416, rs1021632, rs10231253, rs1023964, rs10253781, rs1026254, rs1026255, rs10267678, rs1039147, rs10400909, rs1040211, rs10402271, rs10426094, rs10430148, rs10448254, rs10454797, rs10476994, rs10477463, rs10482042, rs10503040, rs10504376, rs10504377, rs10511964, rs10512156, rs10514883, rs10515026, rs10515029, rs10515386, rs10519170, rs1060455, rs10733121, rs10741175, rs10742719, rs10742722, rs10742725, rs10747215, rs10758596, rs10758597, rs10773829, rs10773890, rs10777410, rs10783282, rs10787629, rs1079022, rs10790519, rs10792084, rs10792267, rs10799801, rs10814235, rs1081900, rs10819162, rs10819173, rs10819174, rs10820403, rs10825816, rs10825817, rs10848219, rs10859338, rs10866514, rs10869422, rs10878636, rs10885864, rs10892873, rs10897003, rs10897020, rs10897049, rs10900908, rs10915495, rs10945913, rs10950253, rs10950254, rs10974449, rs10974859, rs10988348, rs11016132, rs1102617, rs11038193, rs11049049, rs11066247, rs11073964, rs11079804, rs1108209, rs11092309, rs11095608, rs11097396, rs1109916, rs11106228, rs11106700, rs1111218, rs11114028, rs11133030, rs11133248, rs11133602, rs11133822, rs11143837, rs11150971, rs11159907, rs11170973, rs11180553, rs11217627, rs11218016, rs11229192, rs11230180, rs1123024, rs11237698, rs11239751, rs11241620, rs1124165, rs1124166, rs11257695, rs11266413, rs1130371, rs1149736, rs1155098, rs11584403, rs1160985, rs11629688, rs11646101, rs11647759, rs11655913, rs11671804, rs11676819, rs11691971, rs11694165, rs11698059, rs11710973, rs11738432, rs11741205, rs11748700, rs11752453, rs11778430, rs1178520, rs11788891, rs1181913, rs1184766, rs11858967, rs11861905, rs11872966, rs11889938, rs11914999, rs11947861, rs11954932, rs12006950, rs12009590, rs1202525, rs12037204, rs12037869, rs1204331, rs12084240, rs12107500, rs12123186, rs12127313, rs12186632, rs12191684, rs12196957, rs12225299, rs12238307, rs12265862, rs12294703, rs12313149, rs12316258, rs12318549, rs12326462, rs1233078, rs12336107, rs12342299, rs12375106, rs12395571, rs12408105, rs12440774, rs12444393, rs12446552, rs12468287, rs12495316, rs12499442, rs12511743, rs12513052, rs12539316, rs12555462, rs1256424, rs1256428, rs1256444, rs1256447, rs12595616, rs12598082, rs12601300, rs12606449, rs12617390, rs12628020, rs12632665, rs12632797, rs12647148, rs12648659, rs12652190, rs12658719, rs12659288, rs12685147, rs12686342, rs12692593, rs12723357, rs12741415, rs12749061, rs1277307, rs12781952, rs12798784, rs12800777, rs12809801, rs12818087, rs12829992, rs1284059, rs12892914, rs12909713, rs12910825, rs12922082, rs12969851, rs13013898, rs13020250, rs13029092, rs13033552, rs13037545, rs13053558, rs13068144, rs13302146, rs13313001, rs1332249, rs13381188, rs13382950, rs13395944, rs13404031, rs13417560, rs1346440, rs1350089, rs1352576, rs1359651, rs1362729, rs1366413, rs1372254, rs1372567, rs1377334, rs1378169, rs1393360, rs1395773, rs1409427, rs1409428, rs1416770, rs1417032, rs1442063, rs1453013, rs1460191, rs1467737, rs1471994, rs1478281, rs1479560, rs1479831, rs1511556, rs1519812, rs1523314, rs1530914, rs1531347, rs1533822, rs1537989, rs1540125, rs1547329, rs1553497, rs1566106, rs1566430, rs158134, rs1582763, rs1596039, rs1604382, rs1618513, rs1634507, rs1634508, rs167602, rs16830888, rs16834130, rs16841583, rs16852038, rs16852953, rs16854702, rs1685513, rs16857593, rs16863859, rs16863867, rs16864008, rs16879230, rs16879693, rs16889006, rs16900667, rs16901211, rs16914456, rs16918465, rs16931253, rs16931257, rs16931273, rs16943700, rs16950383, rs16951392, rs16959238, rs16964797, rs16971511, rs16979301, rs16983551, rs16995332, rs17016207, rs17025061, rs17034079, rs17039828, rs17042395, rs17048072, rs17056952, rs17087898, rs17091212, rs17091253, rs17091265, rs17095426, rs17095429, rs17098400, rs17105491, rs17117632, rs17133758, rs17135372, rs17137349, rs17145817, rs1719141, rs1719210, rs1719220, rs17207648, rs17236661, rs17237607, rs17253937, rs17255138, rs17317101, rs17332633, rs17383755, rs17410182, rs17431, rs17465431, rs17488034, rs17494056, rs17498815, rs17522996, rs1752653, rs17594509, rs17598123, rs17599877, rs17600575, rs17602572, rs17643262, rs17650435, rs17654608, rs17711743, rs17712565, rs1772988, rs17734389, rs17771318, rs17773314, rs1778596, rs17797399, rs17835266, rs17835397, rs17865911, rs1798021, rs1805952, rs1805957, rs1805960, rs182174, rs1823667, rs1869620, rs1879818, rs1881441, rs1882569, rs1883487, rs1883488, rs1918676, rs1939184, rs1939194, rs1943229, rs1943783, rs1945390, rs1954850, rs1959185, rs1966374, rs1993471, rs1997608, rs2001217, rs2001517, rs200545, rs200547, rs2017823, rs2019707, rs2025466, rs202869, rs2031183, rs2033494, rs2034085, rs2040507, rs2042922, rs2043422, rs2057915, rs2058810, rs2059129, rs2062368, rs2081547, rs2090922, rs2110641, rs2110706, rs2127470, rs2131361, rs2136342, rs2136343, rs2139109, rs2139615, rs2152649, rs2160491, rs2166500, rs217034, rs2181987, rs2203432, rs2204608, rs2213369, rs2224182, rs2232313, rs2234246, rs2242945, rs2250392, rs2252238, rs2267346, rs227103, rs2273235, rs2277365, rs2278583, rs2286276, rs2288522, rs2289711, rs2304935, rs2317481, rs2346709, rs2356132, rs236573, rs2382492, rs2398485, rs2398671, rs2402961, rs2415025, rs2430373, rs2437801, rs2437803, rs2447265, rs2455787, rs2462645, rs2479505, rs2486027, rs2486866, rs2495988, rs2500144, rs2500153, rs2503285, rs252272, rs252950, rs252977, rs2541286, rs2544081, rs2577894, rs2593529, rs2594953, rs2603779, rs2612589, rs2612600, rs2624938, rs2635296, rs264256, rs2649627, rs2653322, rs2694814, rs2712590, rs2728524, rs275467, rs2809591, rs2812237, rs2819190, rs2827879, rs2827881, rs2827882, rs2827909, rs2827911, rs2833325, rs2834330, rs2834341, rs2834344, rs2837995, rs28515995, rs2856044, rs2879724, rs2880301, rs2881458, rs2881599, rs2885856, rs2898441, rs2899683, rs2900285, rs2901098, rs293540, rs293541, rs293542, rs293545, rs2954892, rs2956581, rs2960455, rs298069, rs298185, rs2997967, rs3019879, rs3104993, rs3104996, rs3112160, rs3118077, rs3120733, rs3127080, rs319855, rs319858, rs3208856, rs321325, rs32425, rs3323, rs34661737, rs35306465, rs35393495, rs35762589, rs35775016, rs371298, rs3745546, rs3755311, rs3768235, rs3777530, rs3781533, rs3786954, rs3790971, rs379717, rs3813097, rs3814127, rs3822459, rs3828191, rs3829304, rs3886569, rs3912944, rs3913840, rs394457, rs3960965, rs397118, rs40353, rs40665, rs40666, rs4072688, rs4090174, rs4097545, rs4113946, rs4121392, rs41323947, rs41381844, rs41390747, rs41407844, rs41437548, rs41447448, rs4147047, rs4233036, rs4237493, rs4241009, rs42495, rs4257715, rs4272222, rs4283782, rs4286782, rs4289558, rs4306376, rs4307374, rs4315367, rs4316805, rs4336923, rs4342343, rs4354335, rs4357331, rs4362707, rs4369216, rs4382847, rs4384677, rs4393536, rs4410671, rs4420638, rs4421130, rs4479297, rs4487976, rs4506675, rs4510072, rs4514520, rs4533297, rs4537793, rs4547126, rs4555926, rs4562978, rs456298, rs4576739, rs4639843, rs4643583, rs4648858, rs4648959, rs4652931, rs466093, rs4676320, rs4694116, rs4695895, rs4699882, rs4701641, rs4701734, rs4743641, rs4744768, rs4746100, rs4771531, rs4793734, rs4794225, rs4794346, rs4794347, rs4813394, rs4821990, rs4827479, rs4829946, rs4842993, rs4843267, rs4844600, rs4861498, rs4861864, rs4862558, rs4864737, rs4875330, rs4898337, rs4898872, rs4903240, rs4903243, rs4910821, rs4921744, rs492496, rs4938931, rs4953706, rs4955753, rs4956509, rs4961257, rs4961341, rs4964586, rs4972391, rs4975725, rs4978968, rs4978970, rs4984259, rs5015994, rs508915, rs541965, rs552409, rs558514, rs559664, rs562028, rs5756261, rs5758223, rs5758267, rs5763001, rs589605, rs5907046, rs5910606, rs5910607, rs5910608, rs5935673, rs5945088, rs5951325, rs5955490, rs5956359, rs5962536, rs5964670, rs5966049, rs5978287, rs5981380, rs5981711, rs5987025, rs5991907, rs5992600, rs6022638, rs6039654, rs6075709, rs6082159, rs6094509, rs610352, rs6123167, rs6137147, rs614013, rs617135, rs618499, rs622920, rs624761, rs627178, rs641118, rs642612, rs6430090, rs6451453, rs6458458, rs6473080, rs6479916, rs6498220, rs650943, rs6512077, rs6535872, rs6542225, rs6546889, rs6551575, rs655231, rs6552910, rs6555483, rs6557512, rs6562177, rs6569979, rs6577561, rs6577853, rs6591559, rs6594842, rs6603530, rs6603781, rs6621070, rs6631389, rs6632813, rs6636980, rs6654877, rs6658884, rs6675497, rs6677009, rs667897, rs6683441, rs6689572, rs670139, rs6705923, rs6706570, rs6709683, rs6716363, rs6724143, rs6726524, rs6729547, rs673281, rs6749325, rs676309, rs6770617, rs6796090, rs6800578, rs6800857, rs6817424, rs6828228, rs685859, rs6861510, rs6865969, rs6869793, rs687582, rs6903671, rs6914564, rs6966132, rs6983226, rs6997082, rs7001207, rs7018666, rs7018692, rs7018850, rs7026025, rs7031164, rs7031458, rs703374, rs7040120, rs7044778, rs7051342, rs7061770, rs7064361, rs7069106, rs7070647, rs7071432, rs7076076, rs7082405, rs7084466, rs7084673, rs7086393, rs7106518, rs7108663, rs7120207, rs7123220, rs713952, rs714235, rs7148564, rs7152695, rs7161372, rs7164426, rs717666, rs718376, rs7190355, rs7196364, rs7197825, rs7199809, rs7203844, rs7207413, rs7210605, rs7212136, rs7215182, rs7220146, rs7225545, rs7243684, rs7243917, rs7249558, rs7250661, rs7254358, rs7290458, rs7294982, rs7297136, rs7298828, rs7316571, rs7319447, rs7322229, rs7365975, rs738977, rs7423892, rs7495307, rs7499241, rs7517009, rs7517283, rs7532358, rs7535789, rs7577837, rs7579138, rs7580100, rs759112, rs7595401, rs7603548, rs7606424, rs7615639, rs7625628, rs7648664, rs7666693, rs7674035, rs7679858, rs7694032, rs7699718, rs7702491, rs7722665, rs7726558, rs7734932, rs7737490, rs7753479, rs7773435, rs7821916, rs7824527, rs7825534, rs783376, rs7846493, rs7849193, rs7856017, rs7868954, rs7869556, rs7871777, rs7872516, rs7876084, rs7878331, rs7895861, rs7896662, rs7908601, rs7947761, rs7955859, rs7998410, rs8006542, rs8014761, rs8015610, rs802441, rs802466, rs8042680, rs805530, rs805531, rs8057620, rs8070132, rs8082463, rs8082787, rs8110666, rs8112746, rs8129151, rs820255, rs824631, rs829465, rs829467, rs831480, rs846814, rs846818, rs846825, rs847386, rs848492, rs853389, rs853585, rs865671, rs880293, rs884771, rs890731, rs891088, rs914593, rs9267135, rs9285657, rs9291171, rs9309095, rs9324521, rs9329143, rs9332441, rs9351848, rs9369572, rs9374351, rs9375555, rs9376083, rs9378774, rs9390645, rs9394781, rs9395110, rs9405199, rs9424093, rs9427206, rs942950, rs943218, rs9434717, rs9435127, rs9472557, rs9485905, rs9494139, rs949973, rs950027, rs9504837, rs9520114, rs953362, rs953363, rs9544313, rs9555552, rs957979, rs958935, rs9635948, rs9651104, rs9651363, rs9652690, rs9652691, rs9654458, rs9706460, rs971354, rs9776031, rs9780606, rs9784631, rs9807618, rs980793, rs9812119, rs9812150, rs9842566, rs9872847, rs9889183, rs9896422, rs9898218, rs9899379, rs9904820, rs9909601, rs991110, rs9914336, rs9931815, rs9964709, rs999939, and rs9999758; and
a second probe capable of detecting an E3 allele of APOE;
wherein the probes are affixed to a solid support of a microarray.

9. The set of claim 8, wherein the first probe is capable of detecting a SNP associated with a higher risk of LOAD.

10. The set of claim 9, wherein the second probe is capable of detecting a SNP associated with a lower risk of developing LOAD.

11. The set of claim 8, wherein the first probe and the second probe are capable of detecting a SNP associated with a lower risk of developing LOAD.

12. A set of molecular probes used in assessing the risk of developing late onset Alzheimer's disease (LOAD) comprising:
a first probe for detecting an A allele of rs17042395, wherein a first label is coupled to the first probe; and
a second probe for detecting an E3 allele of APOE wherein a second label is coupled to the second probe;
wherein the presence of both the A allele of rs17042395 and the E3 allele of APOE is associated with a lower risk of developing LOAD, and further wherein the first label and the second label are selected from the group consisting of a radioactive isotope or chelate thereof, a fluorescent dye, a non-fluorescent dye, a stain, an enzyme, a metal, or combinations thereof.

13. A method of classifying a subject to a late onset Alzheimer's disease (LOAD) risk group, comprising:
receiving a sample from the subject;
detecting a first marker consisting of an A allele of rs17042395;
detecting a second marker consisting of an E3 allele of APOE;
classifying the subject in a low LOAD risk group if both the A allele of rs17042395 and the E3 allele of APOE are detected; and
wherein detection of the first marker is provided by a first probe and detection of the second marker is provided by a second probe, the first probe being coupled to a first label and the second probe being coupled to a second label, and further wherein the first label and the second label are selected from the group consisting of a radioactive isotope or chelate thereof, a fluorescent dye, a non-fluorescent dye, a stain, an enzyme, a metal, or combinations thereof.

14. The method of claim 13, further comprising isolating nucleic acid from the sample.

15. The method of claim 13, wherein the first and second markers are detected directly.

16. The method of claim 15, wherein the detecting the markers further comprises a method selected from the group consisting of Sanger sequencing, pyrosequencing, SOLID sequencing, massively parallel sequencing, barcoded DNA sequencing, PCR, real-time PCR, quantitative PCR, microarray analysis of genomic DNA with a gene chip, restriction fragment length polymorphism analysis, allele specific ligation, and comparative genomic hybridization.

17. The method of claim 13, wherein the first and second markers are detected indirectly.

18. The method of claim 17, wherein detecting the markers further comprises a method selected from the group consisting of microarray analysis of RNA, RNA in situ hybridization, RNAse protection assay, Northern blot, reverse transcriptase PCR, quantitative PCR, quantitative reverse transcriptase PCR, quantitative real-time reverse transcriptase PCR, reverse transcriptase treatment followed by direct sequencing, flow cytometry, immunohistochemistry, ELISA, Western blot, immunoaffinity chromatography, HPLC, mass spectrometry, protein microarray analysis, PAGE analysis, isoelectric focusing, and 2-D gel electrophoresis.

19. The set of claim 8, wherein the first probe detects an A allele of rs17042395.